An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.
Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
An adenocarcinoma characterized by the presence of varying combinations of clear and hobnail-shaped tumor cells. There are three predominant patterns described as tubulocystic, solid, and papillary. These tumors, usually located in the female reproductive organs, have been seen more frequently in young women since 1970 as a result of the association with intrauterine exposure to diethylstilbestrol. (From Holland et al., Cancer Medicine, 3d ed)
A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
An adenocarcinoma in which the tumor elements are arranged as finger-like processes or as a solid spherical nodule projecting from an epithelial surface.
Benign proliferation of the ENDOMETRIUM in the UTERUS. Endometrial hyperplasia is classified by its cytology and glandular tissue. There are simple, complex (adenomatous without atypia), and atypical hyperplasia representing also the ascending risk of becoming malignant.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.
A tumor, basically a carcinoma with a single sarcoma such as leiomyosarcoma or angiosarcoma or multiple sarcomas of uterine origin. The role of estrogen has been postulated as a possible etiological factor in this tumor. (Holland et al., Cancer Medicine, 3d ed, p1703)
Tumors or cancer of the UTERUS.
Excision of the uterus.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
A condition in which functional endometrial tissue is present outside the UTERUS. It is often confined to the PELVIS involving the OVARY, the ligaments, cul-de-sac, and the uterovesical peritoneum.
A malignant epithelial tumor with a glandular organization.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
A malignant neoplasm that contains elements of carcinoma and sarcoma so extensively intermixed as to indicate neoplasia of epithelial and mesenchymal tissue. (Stedman, 25th ed)
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
Tumors or cancer of the LIVER.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
The simultaneous analysis of multiple samples of TISSUES or CELLS from BIOPSY or in vitro culture that have been arranged in an array format on slides or microchips.
An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.
A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.
A lipid phosphatase that acts on phosphatidylinositol-3,4,5-trisphosphate to regulate various SIGNAL TRANSDUCTION PATHWAYS. It modulates CELL GROWTH PROCESSES; CELL MIGRATION; and APOPTOSIS. Mutations in PTEN are associated with COWDEN DISEASE and PROTEUS SYNDROME as well as NEOPLASTIC CELL TRANSFORMATION.
A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
Dilatation of the cervix uteri followed by a scraping of the endometrium with a curette.
The mucous membrane lining of the uterine cavity that is hormonally responsive during the MENSTRUAL CYCLE and PREGNANCY. The endometrium undergoes cyclic changes that characterize MENSTRUATION. After successful FERTILIZATION, it serves to sustain the developing embryo.
Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.
Neoplasms containing cyst-like formations or producing mucin or serum.
General term for CYSTS and cystic diseases of the OVARY.
A cell line derived from cultured tumor cells.
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
DNA present in neoplastic tissue.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
A multi-functional catenin that participates in CELL ADHESION and nuclear signaling. Beta catenin binds CADHERINS and helps link their cytoplasmic tails to the ACTIN in the CYTOSKELETON via ALPHA CATENIN. It also serves as a transcriptional co-activator and downstream component of WNT PROTEIN-mediated SIGNAL TRANSDUCTION PATHWAYS.
Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.
Excision of one or both of the FALLOPIAN TUBES.
Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.
Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.
A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.
Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)
Proteins secreted by the epididymal epithelium. These proteins are both tissue- and species-specific. They are important molecular agents in the process of sperm maturation.
The occurrence of highly polymorphic mono- and dinucleotide MICROSATELLITE REPEATS in somatic cells. It is a form of genome instability associated with defects in DNA MISMATCH REPAIR.
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)
Pathological processes that tend eventually to become malignant. (From Dorland, 27th ed)
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)
Cancer or tumors of the URETHRA. Benign epithelial tumors of the urethra usually consist of squamous and transitional cells. Primary urethral carcinomas are rare and typically of squamous cells. Urethral carcinoma is the only urological malignancy that is more common in females than in males.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Tumors or cancer of the NASOPHARYNX.
Tumors or cancer of the THYROID GLAND.
Tumors or cancer of the human BREAST.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Tumors or cancer of the LUNG.
The loss of one allele at a specific locus, caused by a deletion mutation; or loss of a chromosome from a chromosome pair, resulting in abnormal HEMIZYGOSITY. It is detected when heterozygous markers for a locus appear monomorphic because one of the ALLELES was deleted.
A tumor of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumors of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumor of the parotid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575; Holland et al., Cancer Medicine, 3d ed, p1240)
Biochemical identification of mutational changes in a nucleotide sequence.
An expression of the number of mitoses found in a stated number of cells.
Hybridization of a nucleic acid sample to a very large set of OLIGONUCLEOTIDE PROBES, which have been attached individually in columns and rows to a solid support, to determine a BASE SEQUENCE, or to detect variations in a gene sequence, GENE EXPRESSION, or for GENE MAPPING.
Tumors or cancer of the UTERINE CERVIX.
A sarcoma of the body of the uterus arising in older women, composed of more than one mesenchymal tissue, especially including striated muscle cells. It is associated with previous pelvic radiation exposure in 20% of patients. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1702)
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
Genes that inhibit expression of the tumorigenic phenotype. They are normally involved in holding cellular growth in check. When tumor suppressor genes are inactivated or lost, a barrier to normal proliferation is removed and unregulated growth is possible.
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.
A highly malignant, primitive form of carcinoma, probably of germinal cell or teratomatous derivation, usually arising in a gonad and rarely in other sites. It is rare in the female ovary, but in the male it accounts for 20% of all testicular tumors. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, p1595)
Tumors or cancer of the ESOPHAGUS.
Tumors or cancer of the MOUTH.
A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245)
Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives.
Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
A variety of simple repeat sequences that are distributed throughout the GENOME. They are characterized by a short repeat unit of 2-8 basepairs that is repeated up to 100 times. They are also known as short tandem repeats (STRs).
Carbohydrate antigen most commonly seen in tumors of the ovary and occasionally seen in breast, kidney, and gastrointestinal tract tumors and normal tissue. CA 125 is clearly tumor-associated but not tumor-specific.
Carbohydrate antigens expressed by malignant tissue. They are useful as tumor markers and are measured in the serum by means of a radioimmunoassay employing monoclonal antibodies.
A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.
Tumors or cancer of the COLON.
A variant of well-differentiated epidermoid carcinoma that is most common in the oral cavity, but also occurs in the larynx, nasal cavity, esophagus, penis, anorectal region, vulva, vagina, uterine cervix, and skin, especially on the sole of the foot. Most intraoral cases occur in elderly male abusers of smokeless tobacco. The treatment is surgical resection. Radiotherapy is not indicated, as up to 30% treated with radiation become highly aggressive within six months. (Segen, Dictionary of Modern Medicine, 1992)
A poorly differentiated adenocarcinoma in which the nucleus is pressed to one side by a cytoplasmic droplet of mucus. It usually arises in the gastrointestinal system.
Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.
Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus.
Tumors or cancer of the URINARY BLADDER.
A specific pair of GROUP C CHROMOSOMES of the human chromosome classification.
Tumors or cancer of the STOMACH.
Tumors or cancer of the SKIN.
Surgical excision of one or more lymph nodes. Its most common use is in cancer surgery. (From Dorland, 28th ed, p966)
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.
Major constituent of the cytoskeleton found in the cytoplasm of eukaryotic cells. They form a flexible framework for the cell, provide attachment points for organelles and formed bodies, and make communication between parts of the cell possible.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)
They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.
Neoplasms derived from the primitive sex cord or gonadal stromal cells of the embryonic GONADS. They are classified by their presumed histogenesis and differentiation. From the sex cord, there are SERTOLI CELL TUMOR and GRANULOSA CELL TUMOR; from the gonadal stroma, LEYDIG CELL TUMOR and THECOMA. These tumors may be identified in either the OVARY or the TESTIS.
Calcium-dependent cell adhesion proteins. They are important in the formation of ADHERENS JUNCTIONS between cells. Cadherins are classified by their distinct immunological and tissue specificities, either by letters (E- for epithelial, N- for neural, and P- for placental cadherins) or by numbers (cadherin-12 or N-cadherin 2 for brain-cadherin). Cadherins promote cell adhesion via a homophilic mechanism as in the construction of tissues and of the whole animal body.
Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.

Increased expression of the RIalpha subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer. (1/354)

The primary element in the cAMP signal transduction pathway is the cAMP-dependent protein kinase (PKA). Expression of the RIalpha subunit of type I PKA is elevated in a variety of human tumours and cancer cell lines. The purpose of this study was to assess the prognostic importance of RIalpha expression in patients with ovarian cancer. We have evaluated the expression of RIalpha in a panel of human ovarian tumours (n = 40) and five human ovarian cancer cell lines using quantitative reverse transcription polymerase chain reaction (RT-PCR) and Western blot analysis. The human ovarian cell lines OAW42 and OTN14 express high endogenous levels of RIalpha mRNA and protein (at significantly higher mRNA levels than high tissue expressors, P < 0.05). The ovarian cell line A2780 expresses low endogenous levels of RIalpha mRNA and protein (also at higher mRNA levels than low tissue expressors, P < 0.05). Quantitative RT-PCR revealed no significant difference in RIalpha mRNA expression between different ovarian histological subtypes in this study. No associations were found between RIalpha mRNA expression and differentiation state. RIalpha mRNA expression was significantly associated with tumour stage (P = 0.0036), and this remained significant in univariate analysis (P = 0.0002). A trend emerged between RIalpha mRNA expression levels and overall survival in univariate analysis (P = 0.051), however, by multivariate analysis, stage remained the major determinant of overall survival (P = 0.0001). This study indicates that in ovarian epithelial tumours high RIalpha mRNA expression is associated with advanced stage disease. RIalpha expression may be of predictive value in ovarian cancer and may be associated with dysfunctional signalling pathways in this cancer type.  (+info)

Primary endometrioid carcinoma of fallopian tube. Clinicomorphologic study. (2/354)

Twenty cases of primary Fallopian tube endometrioid carcinoma (PFTEC) are presented in the paper. This accounts for 42.5% of all histologic forms of primary Fallopian tube carcinoma (PFTC) found in our Department. The youngest patient was 38, and the oldest 68 years (mean: 56 years). Seven patients were nulliparas. Only two cases were bilateral. According to FIGO staging, 13 cases were evaluated as stage I, 4 as II, and 3 as stage III. Due to the histologic grading, 8 tumors were classified as well, 7 as moderately, and 5 as poorly differentiated. In the time of preparation of the manuscript, 12 women were still alive, 2 of them with recurrent disease. The follow-up of patients without recurrence ranged from 4 to 120 months (median: 63). Eight patients had died (survival time: from 4 to 65 months; median: 26). Metastases were found in 8 patients, especially to ovaries. In 14/20 cases of PFTEC various forms of tubal wall invasion were observed. Blood or lymphatic vessels involvement was found in 9 patients. Six of them had died and one is alive with the symptoms of disease. Immunohistochemical detection of the mutant form of p53 protein and oncogene product, c-erbB-2, was studied in 17 cases. Nine patients exhibited simultaneous p53 protein accumulation and c-erbB-2 expression. 2/9 of these patients are alive with recurrent tumors and 4/9 died. Endometrioid carcinoma of the Fallopian tube can be characterized by a tendency to superficial invasion of tubal wall and in a half of the cases by invasion of vessels. The majority of these tumors were diagnosed at an early stage tumors.  (+info)

Clear cell carcinoma arising in a Cesarean section scar endometriosis: a case report. (3/354)

Endometriosis of a surgical scar is rare and occurs mainly when a hysterectomy or Cesarean section was performed. We describe a 54-year-old woman with a large suprapubic mass as a definite case of a endomerioid carcinoma developing within the scar endometriosis following Cesarean section. Scar endometriosis, as well as endometriosis at other sites, can turn malignant. Endometrioid carcinoma is the most common histological pattern of malignant tumor arising in endometriosis. But clear cell carcinoma is very unusual. A case of primary clear cell carcinoma in endometriosis of a Cesarean section scar is described. To the best of our knowledge, this is the first documented case of endomerioid carcinoma developing within the scar endometriosis in Korea.  (+info)

Overexpression of H-Ryk in mouse fibroblasts confers transforming ability in vitro and in vivo: correlation with up-regulation in epithelial ovarian cancer. (4/354)

Abnormalities in the function of receptor tyrosine kinases (RTKs) have been demonstrated to be important in the pathogenesis of cancer. H-Ryk, a new member of the RTK family, is an unusual RTK in that it is catalytically inactive because of amino acid substitutions of conserved residues in the catalytic domain. We show by immunohistochemistry that it is expressed in the epithelium, stroma, and blood vessels of normal tissues. Evaluation of a panel of 33 primary ovarian tumors (2 benign, 8 borderline, and 23 malignant) was performed. H-Ryk was overexpressed in borderline and malignant ovarian tumors. In serous and clear cell subtypes, there was increased expression in the epithelium, stroma, and blood vessels. Consistent with this observation, overexpression of H-Ryk in the mouse fibroblast cell line NIH3T3 induces anchorage-independent growth and tumorigenicity in nude mice. This implies that overexpression of the receptor can be transforming and may therefore be significant in the pathogenesis of ovarian cancer.  (+info)

beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. (5/354)

The immunohistochemical expression pattern of beta-catenin has been correlated with beta-catenin gene mutations, clinicopathological features, and disease outcome in 69 stage I and II ovarian carcinomas. beta-Catenin expression was localized in the nuclei, in addition to the cytoplasm and membrane, in 11 tumors (16%): nine endometrioid carcinomas with widespread nuclear expression and two serous carcinomas with focal nuclear expression. The remaining 58 carcinomas (84%) only had membranous beta-catenin expression. All but one of the endometrioid carcinomas with nuclear beta-catenin expression had considerable squamous metaplasia, and five of these cases had large areas of endometrioid tumor of low malignant potential. In addition, beta-catenin nuclear expression was observed in atypical epithelial cells in endometriotic glands adjacent to an endometrioid carcinoma. Sequencing was performed on 25 tumors and corresponding normal tissue: all 13 endometrioid tumors as well as 12 carcinomas of other histological types (four serous, two clear cell, two mucinous, and two mixed). There were oncogenic mutations in the phosphorylation sequence for GSK-3beta in exon 3 of the beta-catenin gene in seven endometrioid carcinomas with beta-catenin nuclear expression. Three mutations affected codon 32 (D32G, D32Y, and D32Y), one affected codon 33 (S33C), two affected codon 37 (S37C and S37F), and one affected codon 41 (T41A). No mutations were observed in the other 18 carcinomas analyzed, comprising two endometrioid and two serous carcinomas with beta-catenin nuclear expression, and 14 carcinomas of different histological types with only membranous expression. In the univariate and multivariate survival analyses, beta-catenin nuclear expression was selected as an indicator of good prognosis, because no patient whose tumor expressed beta-catenin in the nuclei showed relapses or died, in contrast to the 19 relapses and deaths among patients with tumors that only had beta-catenin membranous expression, including three of the four patients with endometrioid carcinomas. Oncogenic beta-catenin mutation is characteristic of a group of endometrioid carcinomas with a good prognosis, most of which originate from previous benign or borderline lesions. Endometrioid carcinomas with exclusively membranous expression of beta-catenin seem to represent a different subgroup of carcinomas that probably have a worse prognosis. In early-stage ovarian cancer, determination of the beta-catenin expression pattern could prove to be a useful marker for selecting low-risk patients.  (+info)

Evaluation of the tyrosine kinase domain of the Met proto-oncogene in sporadic ovarian carcinomas*. (6/354)

Most of the ovarian cancers originate from the ovarian surface epithelium derived from the coelomic mesothelium. The Met proto-oncogene encodes a transmembrane tyrosine kinase receptor (Met) that has the capacity to regulate cell proliferation and differentation and it is activated by hepatocyte growth factor. Trisomy of chromosome 7 and Met protein overexpression have been were observed in ovarian carcinomas, the papillary renal cancers and other solid tumors. Frequent mutations of Met proto-oncogene have been found in hereditary papillary renal cancer (HPRC) and most of the mutations are located in the tyrosine kinase domain. The aim of this study to perform a mutation analysis of exons 17 19 of Met proto-oncogene in epithelial ovarian tumors (EOTs). We have examined 24 tumor samples from patients, operated with EOTs. Mutation was detected in exon 18 in only one sample of 24 EOTs. Our results indicate that mutations located in the Met proto-oncogene is not a common event in EOT. It is not clear whether the mutation plays a role in the tumorigenesis or progression of EOT or not.  (+info)

Hormone replacement therapy and risk of epithelial ovarian cancer. (7/354)

It has been suggested that oestrogen replacement therapy is associated with risk of epithelial ovarian cancer of the endometrioid type. Using data from an Australian population-based case-control study, the relation between unopposed oestrogen replacement therapy and epithelial ovarian cancer, both overall and according to histological type, was examined. A total of 793 eligible incident cases of epithelial ovarian cancer diagnosed from 1990 to 1993 among women living in Queensland, New South Wales and Victoria were identified. These were compared with 855 eligible female controls selected at random from the electoral roll, stratified by age and geographic region. Trained interviewers administered standard questionnaires to obtain detailed reproductive and contraceptive histories, as well as details about hormone replacement therapy and pelvic operations. No clear associations were observed between use of hormone replacement therapy overall and risk of ovarian cancer. Unopposed oestrogen replacement therapy was, however, associated with a significant increase in risk of endometrioid or clear cell epithelial ovarian tumours (odds ratio (OR) 2.56; 95% confidence interval (CI) 1.32-4.94). In addition, the risk associated with oestrogen replacement therapy was much larger in women with an intact genital tract (OR 3.00; 95% CI 1.54-5.85) than in those with a history of either hysterectomy or tubal ligation. Post-menopausal oestrogen replacement therapy may, therefore, be a risk factor associated with endometrioid and clear cell tumours in particular. Additionally, the risk may be increased predominantly in women with an intact genital tract. These associations could reflect a possible role of endometriosis in the development of endometrioid or clear cell ovarian tumours.  (+info)

A case-control study of galactose consumption and metabolism in relation to ovarian cancer. (8/354)

Consumption or metabolism of dairy sugar and ovarian cancer have been linked based on evidence that galactose may be toxic to ovarian germ cells and that ovarian cancer is induced in animals by depletion of oocytes. We assessed consumption of dairy products and obtained blood for biochemical and molecular genetic assessment of galactose metabolism in 563 women with newly diagnosed epithelial ovarian cancer and 523 control women selected either by random digit dialing or through lists of residents in eastern Massachusetts and New Hampshire. We observed no significant differences between cases and controls in usual consumption of various types of dairy products or total daily lactose (the principal source of galactose in the diet); nor did we find that RBC activity of either galactose-1-phosphate uridyl transferase (GALT) or galactokinase differed. The mean (and SE) activity of uridine diphospho-galactose 4'-epimerase (in micromoles per hour per gram of hemoglobin) was, however, significantly lower (P < 0.005) in cases compared with controls, 20.32 (0.31) versus 21.64 (0.36). Ovarian cancer cases were also more likely to carry the N314D polymorphism of the GALT gene, generally predisposing to lower GALT activity. The difference was most evident for endometrioid and clear cell types of ovarian cancer, in which 3.9% of cases were found to be homozygous for N314D compared with 0.4% of controls, yielding an odds ratio and 95% confidence interval of 14.17 (2.62-76.60). We conclude that, whereas adult consumption of lactose carries no clear risk for the disease, certain genetic or biochemical features of galactose metabolism may influence disease risk for particular types of ovarian cancer.  (+info)

Carcinoma, endometrioid is a type of cancer that arises from the glandular cells of the endometrium, which is the lining of the uterus. This type of cancer is named for its similarity in appearance to the normal endometrial cells, and it is the second most common type of endometrial cancer after serous carcinoma.

Endometrioid carcinomas are typically divided into different grades based on how abnormal the cells look under a microscope. Low-grade tumors tend to grow more slowly and are less likely to spread beyond the uterus than high-grade tumors.

Risk factors for endometrioid carcinoma include obesity, older age, early menstruation, late menopause, never having been pregnant, and a history of taking estrogen hormone replacement therapy without progesterone. Treatment typically involves surgery to remove the uterus, fallopian tubes, ovaries, and nearby lymph nodes, followed by radiation therapy, chemotherapy, or hormonal therapy in some cases.

Endometrial neoplasms refer to abnormal growths or tumors in the endometrium, which is the innermost lining of the uterus. These neoplasms can be benign (non-cancerous) or malignant (cancerous). The two main types of endometrial cancer are type I, also known as endometrioid adenocarcinoma, and type II, which includes serous carcinoma, clear cell carcinoma, and carcinosarcoma.

Type I endometrial cancers are usually estrogen-dependent and associated with risk factors such as obesity, diabetes, and prolonged exposure to estrogen without progesterone. They tend to grow more slowly and have a better prognosis than type II cancers.

Type II endometrial cancers are less common but more aggressive, often presenting at an advanced stage and having a worse prognosis. They are not typically associated with hormonal factors and may occur in women who have gone through menopause.

Endometrial neoplasms can also include benign growths such as polyps, hyperplasia, and endometriosis. While these conditions are not cancerous, they can increase the risk of developing endometrial cancer and should be monitored closely by a healthcare provider.

Carcinoma is a type of cancer that develops from epithelial cells, which are the cells that line the inner and outer surfaces of the body. These cells cover organs, glands, and other structures within the body. Carcinomas can occur in various parts of the body, including the skin, lungs, breasts, prostate, colon, and pancreas. They are often characterized by the uncontrolled growth and division of abnormal cells that can invade surrounding tissues and spread to other parts of the body through a process called metastasis. Carcinomas can be further classified based on their appearance under a microscope, such as adenocarcinoma, squamous cell carcinoma, and basal cell carcinoma.

Adenocarcinoma, clear cell is a type of cancer that begins in the glandular cells lining various organs and appears "clear" under the microscope due to its characteristic appearance. These cells produce and release mucus or other fluids. This type of cancer can occur in several parts of the body including the lungs, breasts, ovaries, prostate, and kidneys. Clear cell adenocarcinoma is most commonly found in the ovary and accounts for around 5-10% of all ovarian cancers. It is also associated with endometriosis, a condition where tissue similar to the lining of the uterus grows outside the uterine cavity.

Clear cell adenocarcinoma has unique features that distinguish it from other types of cancer. The cells are often large and have distinct borders, giving them a "clear" appearance under the microscope due to their high lipid or glycogen content. This type of cancer tends to be more aggressive than some other forms of adenocarcinoma and may have a poorer prognosis, particularly if it has spread beyond its original site.

Treatment for clear cell adenocarcinoma typically involves surgery to remove the tumor, followed by chemotherapy or radiation therapy to kill any remaining cancer cells. The specific treatment plan will depend on several factors, including the location and stage of the cancer, as well as the patient's overall health and medical history.

Cystadenocarcinoma, serous is a type of cystic tumor that arises from the lining of the abdominal or pelvic cavity (the peritoneum). It is called "serous" because the tumor cells produce a thin, watery fluid similar to serum.

Cystadenocarcinoma is a malignant (cancerous) tumor that can invade surrounding tissues and spread (metastasize) to other parts of the body. It typically affects women over the age of 50 and can cause symptoms such as abdominal pain, bloating, and changes in bowel or bladder habits.

Serous cystadenocarcinoma is a subtype of ovarian cancer that arises from the surface of the ovary. It can also occur in other organs, including the fallopian tubes, peritoneum, and endometrium. This type of tumor tends to grow slowly but can spread widely throughout the abdominal cavity, making it difficult to treat.

Treatment for serous cystadenocarcinoma typically involves surgery to remove the tumor and any affected tissues, followed by chemotherapy to kill any remaining cancer cells. The prognosis for this type of cancer depends on several factors, including the stage of the disease at diagnosis, the patient's age and overall health, and the response to treatment.

Ovarian neoplasms refer to abnormal growths or tumors in the ovary, which can be benign (non-cancerous) or malignant (cancerous). These growths can originate from various cell types within the ovary, including epithelial cells, germ cells, and stromal cells. Ovarian neoplasms are often classified based on their cell type of origin, histological features, and potential for invasive or metastatic behavior.

Epithelial ovarian neoplasms are the most common type and can be further categorized into several subtypes, such as serous, mucinous, endometrioid, clear cell, and Brenner tumors. Some of these epithelial tumors have a higher risk of becoming malignant and spreading to other parts of the body.

Germ cell ovarian neoplasms arise from the cells that give rise to eggs (oocytes) and can include teratomas, dysgerminomas, yolk sac tumors, and embryonal carcinomas. Stromal ovarian neoplasms develop from the connective tissue cells supporting the ovary and can include granulosa cell tumors, thecomas, and fibromas.

It is essential to diagnose and treat ovarian neoplasms promptly, as some malignant forms can be aggressive and potentially life-threatening if not managed appropriately. Regular gynecological exams, imaging studies, and tumor marker tests are often used for early detection and monitoring of ovarian neoplasms. Treatment options may include surgery, chemotherapy, or radiation therapy, depending on the type, stage, and patient's overall health condition.

Squamous cell carcinoma is a type of skin cancer that begins in the squamous cells, which are flat, thin cells that form the outer layer of the skin (epidermis). It commonly occurs on sun-exposed areas such as the face, ears, lips, and backs of the hands. Squamous cell carcinoma can also develop in other areas of the body including the mouth, lungs, and cervix.

This type of cancer usually develops slowly and may appear as a rough or scaly patch of skin, a red, firm nodule, or a sore or ulcer that doesn't heal. While squamous cell carcinoma is not as aggressive as some other types of cancer, it can metastasize (spread) to other parts of the body if left untreated, making early detection and treatment important.

Risk factors for developing squamous cell carcinoma include prolonged exposure to ultraviolet (UV) radiation from the sun or tanning beds, fair skin, a history of sunburns, a weakened immune system, and older age. Prevention measures include protecting your skin from the sun by wearing protective clothing, using a broad-spectrum sunscreen with an SPF of at least 30, avoiding tanning beds, and getting regular skin examinations.

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer in adults. It originates from the hepatocytes, which are the main functional cells of the liver. This type of cancer is often associated with chronic liver diseases such as cirrhosis caused by hepatitis B or C virus infection, alcohol abuse, non-alcoholic fatty liver disease (NAFLD), and aflatoxin exposure.

The symptoms of HCC can vary but may include unexplained weight loss, lack of appetite, abdominal pain or swelling, jaundice, and fatigue. The diagnosis of HCC typically involves imaging tests such as ultrasound, CT scan, or MRI, as well as blood tests to measure alpha-fetoprotein (AFP) levels. Treatment options for Hepatocellular carcinoma depend on the stage and extent of the cancer, as well as the patient's overall health and liver function. Treatment options may include surgery, radiation therapy, chemotherapy, targeted therapy, or liver transplantation.

Papillary cystadenocarcinoma is a type of cancer that arises from the epithelial cells lining a cyst. It is called "papillary" because the tumor has finger-like projections called papillae, which are made up of fibrovascular cores covered by neoplastic cells.

Cystadenocarcinoma is a malignant tumor that has the potential to invade surrounding tissues and spread (metastasize) to other parts of the body. Papillary cystadenocarcinomas can occur in various organs, including the ovaries, pancreas, and lungs.

The symptoms of papillary cystadenocarcinoma depend on the location of the tumor. For example, an ovarian papillary cystadenocarcinoma may cause abdominal pain or bloating, while a lung papillary cystadenocarcinoma may cause coughing or shortness of breath.

The diagnosis of papillary cystadenocarcinoma typically involves imaging tests such as ultrasound, CT scan, or MRI, followed by a biopsy to confirm the presence of cancer cells. Treatment options include surgery to remove the tumor, chemotherapy, and radiation therapy. The prognosis for papillary cystadenocarcinoma depends on several factors, including the stage of the disease at diagnosis, the location of the tumor, and the patient's overall health.

Endometrial hyperplasia is a condition in which the lining of the uterus (endometrium) becomes thickened due to an overgrowth of cells. This occurs as a result of excessive estrogen stimulation without adequate progesterone to balance it. The thickening of the endometrium can range from mild to severe, and in some cases, it may lead to the development of abnormal or precancerous cells.

There are different types of endometrial hyperplasia, including simple hyperplasia, complex hyperplasia, and atypical hyperplasia. Simple hyperplasia has an increased number of glands but no significant architectural distortion, while complex hyperplasia shows crowded glands with architectural complexity. Atypical hyperplasia is a more serious condition characterized by the presence of abnormal cells, which can increase the risk of developing endometrial cancer if left untreated.

The primary symptoms of endometrial hyperplasia include irregular menstrual periods, heavy or prolonged bleeding, and postmenopausal bleeding. The diagnosis typically involves a transvaginal ultrasound and an endometrial biopsy to evaluate the tissue sample for cell changes. Treatment options depend on the type and severity of hyperplasia, as well as the patient's age and overall health. Hormonal therapy, progestin-based medications, or a hysterectomy (surgical removal of the uterus) may be recommended to manage this condition.

Immunohistochemistry (IHC) is a technique used in pathology and laboratory medicine to identify specific proteins or antigens in tissue sections. It combines the principles of immunology and histology to detect the presence and location of these target molecules within cells and tissues. This technique utilizes antibodies that are specific to the protein or antigen of interest, which are then tagged with a detection system such as a chromogen or fluorophore. The stained tissue sections can be examined under a microscope, allowing for the visualization and analysis of the distribution and expression patterns of the target molecule in the context of the tissue architecture. Immunohistochemistry is widely used in diagnostic pathology to help identify various diseases, including cancer, infectious diseases, and immune-mediated disorders.

Adenocarcinoma, mucinous is a type of cancer that begins in the glandular cells that line certain organs and produce mucin, a substance that lubricates and protects tissues. This type of cancer is characterized by the presence of abundant pools of mucin within the tumor. It typically develops in organs such as the colon, rectum, lungs, pancreas, and ovaries.

Mucinous adenocarcinomas tend to have a distinct appearance under the microscope, with large pools of mucin pushing aside the cancer cells. They may also have a different clinical behavior compared to other types of adenocarcinomas, such as being more aggressive or having a worse prognosis in some cases.

It is important to note that while a diagnosis of adenocarcinoma, mucinous can be serious, the prognosis and treatment options may vary depending on several factors, including the location of the cancer, the stage at which it was diagnosed, and the individual's overall health.

Tumor markers are substances that can be found in the body and their presence can indicate the presence of certain types of cancer or other conditions. Biological tumor markers refer to those substances that are produced by cancer cells or by other cells in response to cancer or certain benign (non-cancerous) conditions. These markers can be found in various bodily fluids such as blood, urine, or tissue samples.

Examples of biological tumor markers include:

1. Proteins: Some tumor markers are proteins that are produced by cancer cells or by other cells in response to the presence of cancer. For example, prostate-specific antigen (PSA) is a protein produced by normal prostate cells and in higher amounts by prostate cancer cells.
2. Genetic material: Tumor markers can also include genetic material such as DNA, RNA, or microRNA that are shed by cancer cells into bodily fluids. For example, circulating tumor DNA (ctDNA) is genetic material from cancer cells that can be found in the bloodstream.
3. Metabolites: Tumor markers can also include metabolic products produced by cancer cells or by other cells in response to cancer. For example, lactate dehydrogenase (LDH) is an enzyme that is released into the bloodstream when cancer cells break down glucose for energy.

It's important to note that tumor markers are not specific to cancer and can be elevated in non-cancerous conditions as well. Therefore, they should not be used alone to diagnose cancer but rather as a tool in conjunction with other diagnostic tests and clinical evaluations.

Carcinoma, papillary is a type of cancer that begins in the cells that line the glandular structures or the lining of organs. In a papillary carcinoma, the cancerous cells grow and form small finger-like projections, called papillae, within the tumor. This type of cancer most commonly occurs in the thyroid gland, but can also be found in other organs such as the lung, breast, and kidney. Papillary carcinoma of the thyroid gland is usually slow-growing and has a good prognosis, especially when it is diagnosed at an early stage.

Carcinoma in situ is a medical term used to describe the earliest stage of cancer, specifically a type of cancer that begins in the epithelial tissue, which is the tissue that lines the outer surfaces of organs and body structures. In this stage, the cancer cells are confined to the layer of cells where they first developed and have not spread beyond that layer into the surrounding tissues or organs.

Carcinoma in situ can occur in various parts of the body, including the skin, cervix, breast, lung, prostate, bladder, and other areas. It is often detected through routine screening tests, such as Pap smears for cervical cancer or mammograms for breast cancer.

While carcinoma in situ is not invasive, it can still be a serious condition because it has the potential to develop into an invasive cancer if left untreated. Treatment options for carcinoma in situ may include surgery, radiation therapy, or other forms of treatment, depending on the location and type of cancer. It is important to consult with a healthcare provider to determine the best course of action for each individual case.

A mixed tumor, also known as a mullerian mixed tumor or carcinosarcoma, is a rare type of cancer that occurs most commonly in the female reproductive system. It is called a "mixed" tumor because it contains two or more different types of cells, specifically carcinoma (epithelial) cells and sarcoma (connective tissue) cells. These tumors can arise in the uterus, fallopian tubes, ovaries, or other mullerian-derived structures.

Mullerian mixed tumors are aggressive and have a poor prognosis compared to other types of gynecologic malignancies. They typically occur in postmenopausal women, but can also be found in younger women. Symptoms may include abnormal vaginal bleeding, pelvic pain or pressure, and a mass or bulge in the lower abdomen. Treatment usually involves surgical removal of the tumor, followed by radiation therapy and/or chemotherapy. Regular follow-up care is essential to monitor for recurrence.

Uterine neoplasms refer to abnormal growths in the uterus, which can be benign (non-cancerous) or malignant (cancerous). These growths can originate from different types of cells within the uterus, leading to various types of uterine neoplasms. The two main categories of uterine neoplasms are endometrial neoplasms and uterine sarcomas.

Endometrial neoplasms develop from the endometrium, which is the inner lining of the uterus. Most endometrial neoplasms are classified as endometrioid adenocarcinomas, arising from glandular cells in the endometrium. Other types include serous carcinoma, clear cell carcinoma, and mucinous carcinoma.

Uterine sarcomas, on the other hand, are less common and originate from the connective tissue (stroma) or muscle (myometrium) of the uterus. Uterine sarcomas can be further divided into several subtypes, such as leiomyosarcoma, endometrial stromal sarcoma, and undifferentiated uterine sarcoma.

Uterine neoplasms can cause various symptoms, including abnormal vaginal bleeding or discharge, pelvic pain, and difficulty urinating or having bowel movements. The diagnosis typically involves a combination of imaging tests (such as ultrasound, CT, or MRI scans) and tissue biopsies to determine the type and extent of the neoplasm. Treatment options depend on the type, stage, and patient's overall health but may include surgery, radiation therapy, chemotherapy, or hormone therapy.

A hysterectomy is a surgical procedure that involves the removal of the uterus (womb). Depending on the specific medical condition and necessity, a hysterectomy may also include the removal of the ovaries, fallopian tubes, and surrounding tissues. There are different types of hysterectomies, including:

1. Total hysterectomy: The uterus and cervix are removed.
2. Supracervical (or subtotal) hysterectomy: Only the upper part of the uterus is removed, leaving the cervix intact.
3. Radical hysterectomy: This procedure involves removing the uterus, cervix, surrounding tissues, and the upper part of the vagina. It is typically performed in cases of cervical cancer.
4. Oophorectomy: The removal of one or both ovaries can be performed along with a hysterectomy depending on the patient's medical condition and age.
5. Salpingectomy: The removal of one or both fallopian tubes can also be performed along with a hysterectomy if needed.

The reasons for performing a hysterectomy may include but are not limited to: uterine fibroids, heavy menstrual bleeding, endometriosis, adenomyosis, pelvic prolapse, cervical or uterine cancer, and chronic pelvic pain. The choice of the type of hysterectomy depends on the patient's medical condition, age, and personal preferences.

Neoplasm staging is a systematic process used in medicine to describe the extent of spread of a cancer, including the size and location of the original (primary) tumor and whether it has metastasized (spread) to other parts of the body. The most widely accepted system for this purpose is the TNM classification system developed by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC).

In this system, T stands for tumor, and it describes the size and extent of the primary tumor. N stands for nodes, and it indicates whether the cancer has spread to nearby lymph nodes. M stands for metastasis, and it shows whether the cancer has spread to distant parts of the body.

Each letter is followed by a number that provides more details about the extent of the disease. For example, a T1N0M0 cancer means that the primary tumor is small and has not spread to nearby lymph nodes or distant sites. The higher the numbers, the more advanced the cancer.

Staging helps doctors determine the most appropriate treatment for each patient and estimate the patient's prognosis. It is an essential tool for communication among members of the healthcare team and for comparing outcomes of treatments in clinical trials.

Endometriosis is a medical condition in which tissue similar to the lining of the uterus (endometrium) grows outside the uterine cavity, most commonly on the ovaries, fallopian tubes, and the pelvic peritoneum. This misplaced endometrial tissue continues to act as it would inside the uterus, thickening, breaking down, and bleeding with each menstrual cycle. However, because it is outside the uterus, this blood and tissue have no way to exit the body and can lead to inflammation, scarring, and the formation of adhesions (tissue bands that bind organs together).

The symptoms of endometriosis may include pelvic pain, heavy menstrual periods, painful intercourse, and infertility. The exact cause of endometriosis is not known, but several theories have been proposed, including retrograde menstruation (the backflow of menstrual blood through the fallopian tubes into the pelvic cavity), genetic factors, and immune system dysfunction.

Endometriosis can be diagnosed through a combination of methods, such as medical history, physical examination, imaging tests like ultrasound or MRI, and laparoscopic surgery with tissue biopsy. Treatment options for endometriosis include pain management, hormonal therapies, and surgical intervention to remove the misplaced endometrial tissue. In severe cases, a hysterectomy (removal of the uterus) may be recommended, but this is typically considered a last resort due to its impact on fertility and quality of life.

Adenocarcinoma is a type of cancer that arises from glandular epithelial cells. These cells line the inside of many internal organs, including the breasts, prostate, colon, and lungs. Adenocarcinomas can occur in any of these organs, as well as in other locations where glands are present.

The term "adenocarcinoma" is used to describe a cancer that has features of glandular tissue, such as mucus-secreting cells or cells that produce hormones. These cancers often form glandular structures within the tumor mass and may produce mucus or other substances.

Adenocarcinomas are typically slow-growing and tend to spread (metastasize) to other parts of the body through the lymphatic system or bloodstream. They can be treated with surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these treatments. The prognosis for adenocarcinoma depends on several factors, including the location and stage of the cancer, as well as the patient's overall health and age.

Prognosis is a medical term that refers to the prediction of the likely outcome or course of a disease, including the chances of recovery or recurrence, based on the patient's symptoms, medical history, physical examination, and diagnostic tests. It is an important aspect of clinical decision-making and patient communication, as it helps doctors and patients make informed decisions about treatment options, set realistic expectations, and plan for future care.

Prognosis can be expressed in various ways, such as percentages, categories (e.g., good, fair, poor), or survival rates, depending on the nature of the disease and the available evidence. However, it is important to note that prognosis is not an exact science and may vary depending on individual factors, such as age, overall health status, and response to treatment. Therefore, it should be used as a guide rather than a definitive forecast.

Carcinosarcoma is a rare and aggressive type of cancer that occurs when malignant epithelial cells (carcinoma) coexist with malignant mesenchymal cells (sarcoma) in the same tumor. This mixed malignancy can arise in various organs, but it is most commonly found in the female reproductive tract, particularly in the uterus and ovaries.

In a carcinosarcoma, the epithelial component typically forms glands or nests, while the mesenchymal component can differentiate into various tissue types such as bone, cartilage, muscle, or fat. The presence of both malignant components in the same tumor makes carcinosarcomas particularly aggressive and challenging to treat.

Carcinosarcomas are also known by other names, including sarcomatoid carcinoma, spindle cell carcinoma, or pseudosarcoma. The prognosis for patients with carcinosarcoma is generally poor due to its high propensity for local recurrence and distant metastasis. Treatment usually involves a combination of surgery, radiation therapy, and chemotherapy.

Neoplasm invasiveness is a term used in pathology and oncology to describe the aggressive behavior of cancer cells as they invade surrounding tissues and organs. This process involves the loss of cell-to-cell adhesion, increased motility and migration, and the ability of cancer cells to degrade the extracellular matrix (ECM) through the production of enzymes such as matrix metalloproteinases (MMPs).

Invasive neoplasms are cancers that have spread beyond the original site where they first developed and have infiltrated adjacent tissues or structures. This is in contrast to non-invasive or in situ neoplasms, which are confined to the epithelial layer where they originated and have not yet invaded the underlying basement membrane.

The invasiveness of a neoplasm is an important prognostic factor in cancer diagnosis and treatment, as it can indicate the likelihood of metastasis and the potential effectiveness of various therapies. In general, more invasive cancers are associated with worse outcomes and require more aggressive treatment approaches.

Liver neoplasms refer to abnormal growths in the liver that can be benign or malignant. Benign liver neoplasms are non-cancerous tumors that do not spread to other parts of the body, while malignant liver neoplasms are cancerous tumors that can invade and destroy surrounding tissue and spread to other organs.

Liver neoplasms can be primary, meaning they originate in the liver, or secondary, meaning they have metastasized (spread) to the liver from another part of the body. Primary liver neoplasms can be further classified into different types based on their cell of origin and behavior, including hepatocellular carcinoma, cholangiocarcinoma, and hepatic hemangioma.

The diagnosis of liver neoplasms typically involves a combination of imaging studies, such as ultrasound, CT scan, or MRI, and biopsy to confirm the type and stage of the tumor. Treatment options depend on the type and extent of the neoplasm and may include surgery, radiation therapy, chemotherapy, or liver transplantation.

Neoplastic gene expression regulation refers to the processes that control the production of proteins and other molecules from genes in neoplastic cells, or cells that are part of a tumor or cancer. In a normal cell, gene expression is tightly regulated to ensure that the right genes are turned on or off at the right time. However, in cancer cells, this regulation can be disrupted, leading to the overexpression or underexpression of certain genes.

Neoplastic gene expression regulation can be affected by a variety of factors, including genetic mutations, epigenetic changes, and signals from the tumor microenvironment. These changes can lead to the activation of oncogenes (genes that promote cancer growth and development) or the inactivation of tumor suppressor genes (genes that prevent cancer).

Understanding neoplastic gene expression regulation is important for developing new therapies for cancer, as targeting specific genes or pathways involved in this process can help to inhibit cancer growth and progression.

Tissue Microarray (TMA) analysis is a surgical pathology technique that allows for the simultaneous analysis of multiple tissue samples (known as "cores") from different patients or even different regions of the same tumor, on a single microscope slide. This technique involves the extraction of small cylindrical samples of tissue, which are then arrayed in a grid-like pattern on a recipient paraffin block. Once the TMA is created, sections can be cut and stained with various histochemical or immunohistochemical stains to evaluate the expression of specific proteins or other molecules of interest.

Tissue Array Analysis has become an important tool in biomedical research, enabling high-throughput analysis of tissue samples for molecular markers, gene expression patterns, and other features that can help inform clinical decision making, drug development, and our understanding of disease processes. It's widely used in cancer research to study the heterogeneity of tumors, identify new therapeutic targets, and evaluate patient prognosis.

Carcinoma, ductal, breast is a type of breast cancer that begins in the milk ducts (the tubes that carry milk from the lobules of the breast to the nipple). It is called "ductal" because it starts in the cells that line the milk ducts. Ductal carcinoma can be further classified as either non-invasive or invasive, based on whether the cancer cells are confined to the ducts or have spread beyond them into the surrounding breast tissue.

Non-invasive ductal carcinoma (also known as intraductal carcinoma or ductal carcinoma in situ) is a condition where abnormal cells have been found in the lining of the milk ducts, but they have not spread outside of the ducts. These cells have the potential to become invasive and spread to other parts of the breast or body if left untreated.

Invasive ductal carcinoma (IDC) is a type of breast cancer that starts in a milk duct and then grows into the surrounding breast tissue. From there, it can spread to other parts of the body through the bloodstream and lymphatic system. IDC is the most common form of breast cancer, accounting for about 80% of all cases.

Symptoms of ductal carcinoma may include a lump or thickening in the breast, changes in the size or shape of the breast, dimpling or puckering of the skin on the breast, nipple discharge (especially if it is clear or bloody), and/or redness or scaling of the nipple or breast skin. However, many cases of ductal carcinoma are detected through mammography before any symptoms develop.

Treatment for ductal carcinoma depends on several factors, including the stage and grade of the cancer, as well as the patient's overall health and personal preferences. Treatment options may include surgery (such as a lumpectomy or mastectomy), radiation therapy, chemotherapy, hormone therapy, and/or targeted therapies.

Adenosquamous carcinoma is a rare type of cancer that contains two types of cells: glandular (adeno) and squamous. This mixed composition leads to a unique microscopic appearance and more aggressive behavior compared to other types of carcinomas. Adenosquamous carcinoma can occur in various organs, such as the lung, pancreas, cervix, and skin.

The glandular (adeno) component is made up of columnar epithelial cells that form glands or tubular structures. These cells produce mucus or other secretions. The squamous component consists of flat, scale-like cells that resemble the cells found in the outer layer of the skin.

The presence of both adeno and squamous components in a single tumor can lead to more rapid growth, increased likelihood of metastasis (spreading to other parts of the body), and poorer prognosis compared to carcinomas with only one cell type. Treatment typically involves surgical resection, radiation therapy, chemotherapy, or a combination of these approaches, depending on the location and stage of the cancer.

PTEN phosphohydrolase, also known as PTEN protein or phosphatase and tensin homolog deleted on chromosome ten, is a tumor suppressor protein that plays a crucial role in regulating cell growth and division. It works by dephosphorylating (removing a phosphate group from) the lipid second messenger PIP3, which is involved in signaling pathways that promote cell proliferation and survival. By negatively regulating these pathways, PTEN helps to prevent uncontrolled cell growth and tumor formation. Mutations in the PTEN gene can lead to a variety of cancer types, including breast, prostate, and endometrial cancer.

Carcinoma, basal cell is a type of skin cancer that arises from the basal cells, which are located in the lower part of the epidermis (the outermost layer of the skin). It is also known as basal cell carcinoma (BCC) and is the most common form of skin cancer.

BCC typically appears as a small, shiny, pearly bump or nodule on the skin, often in sun-exposed areas such as the face, ears, neck, hands, and arms. It may also appear as a scar-like area that is white, yellow, or waxy. BCCs are usually slow growing and rarely spread (metastasize) to other parts of the body. However, they can be locally invasive and destroy surrounding tissue if left untreated.

The exact cause of BCC is not known, but it is thought to be related to a combination of genetic and environmental factors, including exposure to ultraviolet (UV) radiation from the sun or tanning beds. People with fair skin, light hair, and blue or green eyes are at increased risk of developing BCC.

Treatment for BCC typically involves surgical removal of the tumor, along with a margin of healthy tissue. Other treatment options may include radiation therapy, topical chemotherapy, or photodynamic therapy. Prevention measures include protecting your skin from UV radiation by wearing protective clothing, using sunscreen, and avoiding tanning beds.

Neoplasms are abnormal growths of cells or tissues that serve no purpose and can be benign (non-cancerous) or malignant (cancerous). Glandular and epithelial neoplasms refer to specific types of tumors that originate from the glandular and epithelial tissues, respectively.

Glandular neoplasms arise from the glandular tissue, which is responsible for producing and secreting substances such as hormones, enzymes, or other fluids. These neoplasms can be further classified into adenomas (benign) and adenocarcinomas (malignant).

Epithelial neoplasms, on the other hand, develop from the epithelial tissue that lines the outer surfaces of organs and the inner surfaces of cavities. These neoplasms can also be benign or malignant and are classified as papillomas (benign) and carcinomas (malignant).

It is important to note that while both glandular and epithelial neoplasms can become cancerous, not all of them do. However, if they do, the malignant versions can invade surrounding tissues and spread to other parts of the body, making them potentially life-threatening.

Mucinous cystadenocarcinoma is a type of cancer that arises from the mucin-producing cells in the lining of a cyst. It is a subtype of cystadenocarcinoma, which is a malignant tumor that develops within a cyst. Mucinous cystadenocarcinomas are typically found in the ovary or pancreas but can also occur in other organs such as the appendix and the respiratory tract.

These tumors are characterized by the production of large amounts of mucin, a gel-like substance that can accumulate within the cyst and cause it to grow. Mucinous cystadenocarcinomas tend to grow slowly but can become quite large and may eventually spread (metastasize) to other parts of the body if left untreated.

Symptoms of mucinous cystadenocarcinoma depend on the location and size of the tumor, but they may include abdominal pain or discomfort, bloating, changes in bowel movements, or vaginal bleeding. Treatment typically involves surgical removal of the tumor, followed by chemotherapy or radiation therapy to kill any remaining cancer cells. The prognosis for mucinous cystadenocarcinoma depends on several factors, including the stage of the disease at diagnosis and the patient's overall health.

Dilatation and Curettage (D&C) is a medical procedure commonly performed on the uterus. The term "dilatation" refers to the widening or opening of the cervix, which is the lower part of the uterus that opens into the vagina. This is achieved using dilators, which are gradually inserted into the cervical canal to stretch it open.

The term "curettage" refers to the scraping or suctioning out of tissue from the lining of the uterus (endometrium). A curette, a long, loop-shaped surgical instrument, is used to scrape the lining, or suction equipment may be used to remove the tissue.

A D&C procedure is typically performed to diagnose and treat various conditions affecting the uterus, such as abnormal uterine bleeding, heavy menstrual periods, endometrial hyperplasia, or to remove residual tissue after a miscarriage or abortion. It's usually a minor surgical procedure that can be done in a hospital, clinic, or doctor's office, and is often performed under local anesthesia, conscious sedation, or general anesthesia depending on the situation and patient preference.

The endometrium is the innermost layer of the uterus, which lines the uterine cavity and has a critical role in the menstrual cycle and pregnancy. It is composed of glands and blood vessels that undergo cyclic changes under the influence of hormones, primarily estrogen and progesterone. During the menstrual cycle, the endometrium thickens in preparation for a potential pregnancy. If fertilization does not occur, it will break down and be shed, resulting in menstruation. In contrast, if implantation takes place, the endometrium provides essential nutrients to support the developing embryo and placenta throughout pregnancy.

Neoplasm grading is a system used by pathologists to classify the degree of abnormality in cells that make up a tumor (neoplasm). It provides an assessment of how quickly the tumor is likely to grow and spread. The grade helps doctors predict the prognosis and determine the best treatment options.

Neoplasm grading typically involves evaluating certain cellular features under a microscope, such as:

1. Differentiation or degree of maturity: This refers to how closely the tumor cells resemble their normal counterparts in terms of size, shape, and organization. Well-differentiated tumors have cells that look more like normal cells and are usually slower growing. Poorly differentiated tumors have cells that appear very abnormal and tend to grow and spread more aggressively.

2. Mitotic count: This is the number of times the tumor cells divide (mitosis) within a given area. A higher mitotic count indicates a faster-growing tumor.

3. Necrosis: This refers to areas of dead tissue within the tumor. A significant amount of necrosis may suggest a more aggressive tumor.

Based on these and other factors, pathologists assign a grade to the tumor using a standardized system, such as the Bloom-Richardson or Scarff-Bloom-Richardson grading systems for breast cancer or the Fuhrman grading system for kidney cancer. The grade usually consists of a number or a range (e.g., G1, G2, G3, or G4) or a combination of grades (e.g., low grade, intermediate grade, and high grade).

In general, higher-grade tumors have a worse prognosis than lower-grade tumors because they are more likely to grow quickly, invade surrounding tissues, and metastasize (spread) to other parts of the body. However, neoplasm grading is just one aspect of cancer diagnosis and treatment planning. Other factors, such as the stage of the disease, location of the tumor, patient's overall health, and specific molecular markers, are also considered when making treatment decisions.

Neoplasms: Neoplasms refer to abnormal growths of tissue that can be benign (non-cancerous) or malignant (cancerous). They occur when the normal control mechanisms that regulate cell growth and division are disrupted, leading to uncontrolled cell proliferation.

Cystic Neoplasms: Cystic neoplasms are tumors that contain fluid-filled sacs or cysts. These tumors can be benign or malignant and can occur in various organs of the body, including the pancreas, ovary, and liver.

Mucinous Neoplasms: Mucinous neoplasms are a type of cystic neoplasm that is characterized by the production of mucin, a gel-like substance produced by certain types of cells. These tumors can occur in various organs, including the ovary, pancreas, and colon. Mucinous neoplasms can be benign or malignant, and malignant forms are often aggressive and have a poor prognosis.

Serous Neoplasms: Serous neoplasms are another type of cystic neoplasm that is characterized by the production of serous fluid, which is a thin, watery fluid. These tumors commonly occur in the ovary and can be benign or malignant. Malignant serous neoplasms are often aggressive and have a poor prognosis.

In summary, neoplasms refer to abnormal tissue growths that can be benign or malignant. Cystic neoplasms contain fluid-filled sacs and can occur in various organs of the body. Mucinous neoplasms produce a gel-like substance called mucin and can also occur in various organs, while serous neoplasms produce thin, watery fluid and commonly occur in the ovary. Both mucinous and serous neoplasms can be benign or malignant, with malignant forms often being aggressive and having a poor prognosis.

An ovarian cyst is a sac or pouch filled with fluid that forms on the ovary. Ovarian cysts are quite common in women during their childbearing years, and they often cause no symptoms. In most cases, ovarian cysts disappear without treatment over a few months. However, larger or persistent cysts may require medical intervention, including surgical removal.

There are various types of ovarian cysts, such as functional cysts (follicular and corpus luteum cysts), which develop during the menstrual cycle due to hormonal changes, and non-functional cysts (dermoid cysts, endometriomas, and cystadenomas), which can form due to different causes.

While many ovarian cysts are benign, some may have malignant potential or indicate an underlying medical condition like polycystic ovary syndrome (PCOS). Regular gynecological check-ups, including pelvic examinations and ultrasounds, can help detect and monitor ovarian cysts.

A cell line that is derived from tumor cells and has been adapted to grow in culture. These cell lines are often used in research to study the characteristics of cancer cells, including their growth patterns, genetic changes, and responses to various treatments. They can be established from many different types of tumors, such as carcinomas, sarcomas, and leukemias. Once established, these cell lines can be grown and maintained indefinitely in the laboratory, allowing researchers to conduct experiments and studies that would not be feasible using primary tumor cells. It is important to note that tumor cell lines may not always accurately represent the behavior of the original tumor, as they can undergo genetic changes during their time in culture.

Transitional cell carcinoma (TCC) is a type of cancer that develops in the transitional epithelium, which is the tissue that lines the inner surface of the urinary tract. This includes the renal pelvis, ureters, bladder, and urethra. Transitional cell carcinoma is the most common type of bladder cancer and can also occur in other parts of the urinary system.

Transitional cells are specialized epithelial cells that can stretch and change shape as the organs they line expand or contract. These cells normally have a flat, squamous appearance when at rest but become more cuboidal and columnar when the organ is full. Transitional cell carcinomas typically start in the urothelium, which is the innermost lining of the urinary tract.

Transitional cell carcinoma can be classified as non-invasive (also called papillary or superficial), invasive, or both. Non-invasive TCCs are confined to the urothelium and have not grown into the underlying connective tissue. Invasive TCCs have grown through the urothelium and invaded the lamina propria (a layer of connective tissue beneath the urothelium) or the muscle wall of the bladder.

Transitional cell carcinoma can also be categorized as low-grade or high-grade, depending on how abnormal the cancer cells look under a microscope and how likely they are to grow and spread. Low-grade TCCs tend to have a better prognosis than high-grade TCCs.

Treatment for transitional cell carcinoma depends on the stage and grade of the cancer, as well as other factors such as the patient's overall health. Treatment options may include surgery, radiation therapy, chemotherapy, or immunotherapy.

The term "DNA, neoplasm" is not a standard medical term or concept. DNA refers to deoxyribonucleic acid, which is the genetic material present in the cells of living organisms. A neoplasm, on the other hand, is a tumor or growth of abnormal tissue that can be benign (non-cancerous) or malignant (cancerous).

In some contexts, "DNA, neoplasm" may refer to genetic alterations found in cancer cells. These genetic changes can include mutations, amplifications, deletions, or rearrangements of DNA sequences that contribute to the development and progression of cancer. Identifying these genetic abnormalities can help doctors diagnose and treat certain types of cancer more effectively.

However, it's important to note that "DNA, neoplasm" is not a term that would typically be used in medical reports or research papers without further clarification. If you have any specific questions about DNA changes in cancer cells or neoplasms, I would recommend consulting with a healthcare professional or conducting further research on the topic.

Multiple primary neoplasms refer to the occurrence of more than one primary malignant tumor in an individual, where each tumor is unrelated to the other and originates from separate cells or organs. This differs from metastatic cancer, where a single malignancy spreads to multiple sites in the body. Multiple primary neoplasms can be synchronous (occurring at the same time) or metachronous (occurring at different times). The risk of developing multiple primary neoplasms increases with age and is associated with certain genetic predispositions, environmental factors, and lifestyle choices such as smoking and alcohol consumption.

Beta-catenin is a protein that plays a crucial role in gene transcription and cell-cell adhesion. It is a key component of the Wnt signaling pathway, which regulates various processes such as cell proliferation, differentiation, and migration during embryonic development and tissue homeostasis in adults.

In the absence of Wnt signals, beta-catenin forms a complex with other proteins, including adenomatous polyposis coli (APC) and axin, which targets it for degradation by the proteasome. When Wnt ligands bind to their receptors, this complex is disrupted, allowing beta-catenin to accumulate in the cytoplasm and translocate to the nucleus. In the nucleus, beta-catenin interacts with T cell factor/lymphoid enhancer-binding factor (TCF/LEF) transcription factors to activate the transcription of target genes involved in cell fate determination, survival, and proliferation.

Mutations in the genes encoding components of the Wnt signaling pathway, including beta-catenin, have been implicated in various human diseases, such as cancer, developmental disorders, and degenerative conditions.

Lymphatic metastasis is the spread of cancer cells from a primary tumor to distant lymph nodes through the lymphatic system. It occurs when malignant cells break away from the original tumor, enter the lymphatic vessels, and travel to nearby or remote lymph nodes. Once there, these cancer cells can multiply and form new tumors, leading to further progression of the disease. Lymphatic metastasis is a common way for many types of cancer to spread and can have significant implications for prognosis and treatment strategies.

Salpingectomy is a surgical procedure in which one or both of the fallopian tubes are removed. These tubes are slender structures that connect the ovaries to the uterus, through which the egg travels from the ovary to the uterus during ovulation. Salpingectomy can be performed for various reasons such as ectopic pregnancy, salpingitis (inflammation of the fallopian tubes), hydrosalpinx (fluid-filled tube), or as a preventative measure in women with increased risk of ovarian cancer. The procedure can be carried out through laparoscopy, hysteroscopy, or laparotomy, depending on the patient's condition and the surgeon's preference.

Carcinoma, bronchogenic is a medical term that refers to a type of lung cancer that originates in the bronchi, which are the branching tubes that carry air into the lungs. It is the most common form of lung cancer and can be further classified into different types based on the specific cell type involved, such as squamous cell carcinoma, adenocarcinoma, or large cell carcinoma.

Bronchogenic carcinomas are often associated with smoking and exposure to environmental pollutants, although they can also occur in non-smokers. Symptoms may include coughing, chest pain, shortness of breath, wheezing, hoarseness, or unexplained weight loss. Treatment options depend on the stage and location of the cancer, as well as the patient's overall health and may include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these approaches.

Tumor suppressor protein p53, also known as p53 or tumor protein p53, is a nuclear phosphoprotein that plays a crucial role in preventing cancer development and maintaining genomic stability. It does so by regulating the cell cycle and acting as a transcription factor for various genes involved in apoptosis (programmed cell death), DNA repair, and cell senescence (permanent cell growth arrest).

In response to cellular stress, such as DNA damage or oncogene activation, p53 becomes activated and accumulates in the nucleus. Activated p53 can then bind to specific DNA sequences and promote the transcription of target genes that help prevent the proliferation of potentially cancerous cells. These targets include genes involved in cell cycle arrest (e.g., CDKN1A/p21), apoptosis (e.g., BAX, PUMA), and DNA repair (e.g., GADD45).

Mutations in the TP53 gene, which encodes p53, are among the most common genetic alterations found in human cancers. These mutations often lead to a loss or reduction of p53's tumor suppressive functions, allowing cancer cells to proliferate uncontrollably and evade apoptosis. As a result, p53 has been referred to as "the guardian of the genome" due to its essential role in preventing tumorigenesis.

Intraductal carcinoma, noninfiltrating is a medical term used to describe a type of breast cancer that is confined to the milk ducts of the breast. It is also sometimes referred to as ductal carcinoma in situ (DCIS). Noninfiltrating means that the cancer cells have not spread beyond the ducts into the surrounding breast tissue or elsewhere in the body.

In this type of cancer, abnormal cells line the milk ducts and fill the inside of the ducts. These abnormal cells may look like cancer cells under a microscope, but they have not grown through the walls of the ducts into the surrounding breast tissue. However, if left untreated, noninfiltrating intraductal carcinoma can progress to an invasive form of breast cancer where the cancer cells spread beyond the milk ducts and invade the surrounding breast tissue.

It is important to note that while noninfiltrating intraductal carcinoma is considered a precancerous condition, it still requires medical treatment to prevent the development of invasive breast cancer. Treatment options may include surgery, radiation therapy, or hormone therapy, depending on the size and location of the tumor and other individual factors.

Adenoid cystic carcinoma (AdCC) is a rare type of cancer that can occur in various glands and tissues of the body, most commonly in the salivary glands. AdCC is characterized by its slow growth and tendency to spread along nerves. It typically forms solid, cystic, or mixed tumors with distinct histological features, including epithelial cells arranged in tubular, cribriform, or solid patterns.

The term "carcinoma" refers to a malignant tumor originating from the epithelial cells lining various organs and glands. In this case, adenoid cystic carcinoma is a specific type of carcinoma that arises in the salivary glands or other glandular tissues.

The primary treatment options for AdCC include surgical resection, radiation therapy, and sometimes chemotherapy. Despite its slow growth, adenoid cystic carcinoma has a propensity to recur locally and metastasize to distant sites such as the lungs, bones, and liver. Long-term follow-up is essential due to the risk of late recurrences.

Epididymal secretory proteins (ESPs) are a group of proteins that are produced and secreted by the epididymis, a long, coiled tube that lies alongside the testicle in males. The epididymis is responsible for maturing sperm cells after they have been produced in the testes.

The ESPs play a crucial role in this maturation process by interacting with the sperm and promoting their motility, survival, and fertilizing ability. These proteins are thought to protect sperm from damage during their transit through the male reproductive tract and also help to prepare them for fertilization of the egg in the female reproductive tract.

The ESPs include a variety of different protein types, such as enzymes, binding proteins, and structural proteins. Some of the specific ESPs that have been identified and studied include epididymal secretory protein E1 (also known as HE1), epididymal protease inhibitor, and lactoferrin.

Abnormalities in the expression or function of ESPs have been associated with male infertility, highlighting their importance in reproductive health.

Microsatellite instability (MSI) is a genetic phenomenon characterized by alterations in the number of repeat units in microsatellites, which are short repetitive DNA sequences distributed throughout the genome. MSI arises due to defects in the DNA mismatch repair system, leading to accumulation of errors during DNA replication and cell division.

This condition is often associated with certain types of cancer, such as colorectal, endometrial, and gastric cancers. The presence of MSI in tumors may indicate a better prognosis and potential response to immunotherapy, particularly those targeting PD-1 or PD-L1 pathways.

MSI is typically determined through molecular testing, which compares the length of microsatellites in normal and tumor DNA samples. A high level of instability, known as MSI-High (MSI-H), is indicative of a dysfunctional mismatch repair system and increased likelihood of cancer development.

Carcinoma, small cell is a type of lung cancer that typically starts in the bronchi (the airways that lead to the lungs). It is called "small cell" because the cancer cells are small and appear round or oval in shape. This type of lung cancer is also sometimes referred to as "oat cell carcinoma" due to the distinctive appearance of the cells, which can resemble oats when viewed under a microscope.

Small cell carcinoma is a particularly aggressive form of lung cancer that tends to spread quickly to other parts of the body. It is strongly associated with smoking and is less common than non-small cell lung cancer (NSCLC), which accounts for about 85% of all lung cancers.

Like other types of lung cancer, small cell carcinoma may not cause any symptoms in its early stages. However, as the tumor grows and spreads, it can cause a variety of symptoms, including coughing, chest pain, shortness of breath, hoarseness, and weight loss. Treatment for small cell carcinoma typically involves a combination of chemotherapy, radiation therapy, and sometimes surgery.

Immunoenzyme techniques are a group of laboratory methods used in immunology and clinical chemistry that combine the specificity of antibody-antigen reactions with the sensitivity and amplification capabilities of enzyme reactions. These techniques are primarily used for the detection, quantitation, or identification of various analytes (such as proteins, hormones, drugs, viruses, or bacteria) in biological samples.

In immunoenzyme techniques, an enzyme is linked to an antibody or antigen, creating a conjugate. This conjugate then interacts with the target analyte in the sample, forming an immune complex. The presence and amount of this immune complex can be visualized or measured by detecting the enzymatic activity associated with it.

There are several types of immunoenzyme techniques, including:

1. Enzyme-linked Immunosorbent Assay (ELISA): A widely used method for detecting and quantifying various analytes in a sample. In ELISA, an enzyme is attached to either the capture antibody or the detection antibody. After the immune complex formation, a substrate is added that reacts with the enzyme, producing a colored product that can be measured spectrophotometrically.
2. Immunoblotting (Western blot): A method used for detecting specific proteins in a complex mixture, such as a protein extract from cells or tissues. In this technique, proteins are separated by gel electrophoresis and transferred to a membrane, where they are probed with an enzyme-conjugated antibody directed against the target protein.
3. Immunohistochemistry (IHC): A method used for detecting specific antigens in tissue sections or cells. In IHC, an enzyme-conjugated primary or secondary antibody is applied to the sample, and the presence of the antigen is visualized using a chromogenic substrate that produces a colored product at the site of the antigen-antibody interaction.
4. Immunofluorescence (IF): A method used for detecting specific antigens in cells or tissues by employing fluorophore-conjugated antibodies. The presence of the antigen is visualized using a fluorescence microscope.
5. Enzyme-linked immunosorbent assay (ELISA): A method used for detecting and quantifying specific antigens or antibodies in liquid samples, such as serum or culture supernatants. In ELISA, an enzyme-conjugated detection antibody is added after the immune complex formation, and a substrate is added that reacts with the enzyme to produce a colored product that can be measured spectrophotometrically.

These techniques are widely used in research and diagnostic laboratories for various applications, including protein characterization, disease diagnosis, and monitoring treatment responses.

Medullary carcinoma is a type of cancer that develops in the neuroendocrine cells of the thyroid gland. These cells produce hormones that help regulate various bodily functions. Medullary carcinoma is a relatively rare form of thyroid cancer, accounting for about 5-10% of all cases.

Medullary carcinoma is characterized by the presence of certain genetic mutations that cause the overproduction of calcitonin, a hormone produced by the neuroendocrine cells. This overproduction can lead to the formation of tumors in the thyroid gland.

Medullary carcinoma can be hereditary or sporadic. Hereditary forms of the disease are caused by mutations in the RET gene and are often associated with multiple endocrine neoplasia type 2 (MEN 2), a genetic disorder that affects the thyroid gland, adrenal glands, and parathyroid glands. Sporadic forms of medullary carcinoma, on the other hand, are not inherited and occur randomly in people with no family history of the disease.

Medullary carcinoma is typically more aggressive than other types of thyroid cancer and tends to spread (metastasize) to other parts of the body, such as the lymph nodes, lungs, and liver. Symptoms may include a lump or nodule in the neck, difficulty swallowing, hoarseness, and coughing. Treatment options may include surgery, radiation therapy, and chemotherapy. Regular monitoring of calcitonin levels is also recommended to monitor the effectiveness of treatment and detect any recurrence of the disease.

Retrospective studies, also known as retrospective research or looking back studies, are a type of observational study that examines data from the past to draw conclusions about possible causal relationships between risk factors and outcomes. In these studies, researchers analyze existing records, medical charts, or previously collected data to test a hypothesis or answer a specific research question.

Retrospective studies can be useful for generating hypotheses and identifying trends, but they have limitations compared to prospective studies, which follow participants forward in time from exposure to outcome. Retrospective studies are subject to biases such as recall bias, selection bias, and information bias, which can affect the validity of the results. Therefore, retrospective studies should be interpreted with caution and used primarily to generate hypotheses for further testing in prospective studies.

Medical survival rate is a statistical measure used to determine the percentage of patients who are still alive for a specific period of time after their diagnosis or treatment for a certain condition or disease. It is often expressed as a five-year survival rate, which refers to the proportion of people who are alive five years after their diagnosis. Survival rates can be affected by many factors, including the stage of the disease at diagnosis, the patient's age and overall health, the effectiveness of treatment, and other health conditions that the patient may have. It is important to note that survival rates are statistical estimates and do not necessarily predict an individual patient's prognosis.

Carcinoma, lobular is a type of breast cancer that begins in the milk-producing glands (lobules) of the breast. It can be either invasive or non-invasive (in situ). Invasive lobular carcinoma (ILC) occurs when the cancer cells break through the wall of the lobule and invade the surrounding breast tissue, and can potentially spread to other parts of the body. Non-invasive lobular carcinoma (LCIS), on the other hand, refers to the presence of abnormal cells within the lobule that have not invaded nearby breast tissue.

ILC is usually detected as a mass or thickening in the breast, and it may not cause any symptoms or show up on mammograms until it has grown quite large. It tends to grow more slowly than some other types of breast cancer, but it can still be serious and require extensive treatment. LCIS does not typically cause any symptoms and is usually found during a biopsy performed for another reason.

Treatment options for carcinoma, lobular depend on several factors, including the stage of the cancer, the patient's overall health, and their personal preferences. Treatment may include surgery, radiation therapy, chemotherapy, hormone therapy, or targeted therapy. Regular follow-up care is essential to monitor for recurrence or the development of new cancers.

A precancerous condition, also known as a premalignant condition, is a state of abnormal cellular growth and development that has a higher-than-normal potential to progress into cancer. These conditions are characterized by the presence of certain anomalies in the cells, such as dysplasia (abnormal changes in cell shape or size), which can indicate an increased risk for malignant transformation.

It is important to note that not all precancerous conditions will eventually develop into cancer, and some may even regress on their own. However, individuals with precancerous conditions are often at a higher risk of developing cancer compared to the general population. Regular monitoring and appropriate medical interventions, if necessary, can help manage this risk and potentially prevent or detect cancer at an early stage when it is more treatable.

Examples of precancerous conditions include:

1. Dysplasia in the cervix (cervical intraepithelial neoplasia or CIN)
2. Atypical ductal hyperplasia or lobular hyperplasia in the breast
3. Actinic keratosis on the skin
4. Leukoplakia in the mouth
5. Barrett's esophagus in the digestive tract

Regular medical check-ups, screenings, and lifestyle modifications are crucial for individuals with precancerous conditions to monitor their health and reduce the risk of cancer development.

A neoplasm is a tumor or growth that is formed by an abnormal and excessive proliferation of cells, which can be benign or malignant. Neoplasm proteins are therefore any proteins that are expressed or produced in these neoplastic cells. These proteins can play various roles in the development, progression, and maintenance of neoplasms.

Some neoplasm proteins may contribute to the uncontrolled cell growth and division seen in cancer, such as oncogenic proteins that promote cell cycle progression or inhibit apoptosis (programmed cell death). Others may help the neoplastic cells evade the immune system, allowing them to proliferate undetected. Still others may be involved in angiogenesis, the formation of new blood vessels that supply the tumor with nutrients and oxygen.

Neoplasm proteins can also serve as biomarkers for cancer diagnosis, prognosis, or treatment response. For example, the presence or level of certain neoplasm proteins in biological samples such as blood or tissue may indicate the presence of a specific type of cancer, help predict the likelihood of cancer recurrence, or suggest whether a particular therapy will be effective.

Overall, understanding the roles and behaviors of neoplasm proteins can provide valuable insights into the biology of cancer and inform the development of new diagnostic and therapeutic strategies.

A mutation is a permanent change in the DNA sequence of an organism's genome. Mutations can occur spontaneously or be caused by environmental factors such as exposure to radiation, chemicals, or viruses. They may have various effects on the organism, ranging from benign to harmful, depending on where they occur and whether they alter the function of essential proteins. In some cases, mutations can increase an individual's susceptibility to certain diseases or disorders, while in others, they may confer a survival advantage. Mutations are the driving force behind evolution, as they introduce new genetic variability into populations, which can then be acted upon by natural selection.

Local neoplasm recurrence is the return or regrowth of a tumor in the same location where it was originally removed or treated. This means that cancer cells have survived the initial treatment and started to grow again in the same area. It's essential to monitor and detect any local recurrence as early as possible, as it can affect the prognosis and may require additional treatment.

Neoplastic cell transformation is a process in which a normal cell undergoes genetic alterations that cause it to become cancerous or malignant. This process involves changes in the cell's DNA that result in uncontrolled cell growth and division, loss of contact inhibition, and the ability to invade surrounding tissues and metastasize (spread) to other parts of the body.

Neoplastic transformation can occur as a result of various factors, including genetic mutations, exposure to carcinogens, viral infections, chronic inflammation, and aging. These changes can lead to the activation of oncogenes or the inactivation of tumor suppressor genes, which regulate cell growth and division.

The transformation of normal cells into cancerous cells is a complex and multi-step process that involves multiple genetic and epigenetic alterations. It is characterized by several hallmarks, including sustained proliferative signaling, evasion of growth suppressors, resistance to cell death, enabling replicative immortality, induction of angiogenesis, activation of invasion and metastasis, reprogramming of energy metabolism, and evading immune destruction.

Neoplastic cell transformation is a fundamental concept in cancer biology and is critical for understanding the molecular mechanisms underlying cancer development and progression. It also has important implications for cancer diagnosis, prognosis, and treatment, as identifying the specific genetic alterations that underlie neoplastic transformation can help guide targeted therapies and personalized medicine approaches.

Carcinoma, neuroendocrine is a type of cancer that arises from the neuroendocrine cells, which are specialized cells that have both nerve and hormone-producing functions. These cells are found throughout the body, but neuroendocrine tumors (NETs) most commonly occur in the lungs, gastrointestinal tract, pancreas, and thyroid gland.

Neuroendocrine carcinomas can be classified as well-differentiated or poorly differentiated based on how closely they resemble normal neuroendocrine cells under a microscope. Well-differentiated tumors tend to grow more slowly and are less aggressive than poorly differentiated tumors.

Neuroendocrine carcinomas can produce and release hormones and other substances that can cause a variety of symptoms, such as flushing, diarrhea, wheezing, and heart palpitations. Treatment for neuroendocrine carcinoma depends on the location and extent of the tumor, as well as the patient's overall health. Treatment options may include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these approaches.

Urethral neoplasms refer to abnormal growths or tumors in the urethra, which is the tube that carries urine from the bladder out of the body. These growths can be benign (non-cancerous) or malignant (cancerous).

Benign urethral neoplasms may include conditions such as urethral polyps or papillomas, which are usually not life-threatening and can often be removed with surgery.

Malignant urethral neoplasms, on the other hand, are cancerous tumors that can invade surrounding tissues and spread to other parts of the body. These include urethral carcinomas, which can be further classified into different types such as squamous cell carcinoma, transitional cell carcinoma, and adenocarcinoma, depending on the type of cells involved.

Urethral neoplasms are relatively rare, but when they do occur, they can cause a variety of symptoms such as difficulty urinating, blood in the urine, pain during urination or sexual intercourse, and discharge from the urethra. Treatment options depend on the type, location, and stage of the neoplasm, and may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Survival analysis is a branch of statistics that deals with the analysis of time to event data. It is used to estimate the time it takes for a certain event of interest to occur, such as death, disease recurrence, or treatment failure. The event of interest is called the "failure" event, and survival analysis estimates the probability of not experiencing the failure event until a certain point in time, also known as the "survival" probability.

Survival analysis can provide important information about the effectiveness of treatments, the prognosis of patients, and the identification of risk factors associated with the event of interest. It can handle censored data, which is common in medical research where some participants may drop out or be lost to follow-up before the event of interest occurs.

Survival analysis typically involves estimating the survival function, which describes the probability of surviving beyond a certain time point, as well as hazard functions, which describe the instantaneous rate of failure at a given time point. Other important concepts in survival analysis include median survival times, restricted mean survival times, and various statistical tests to compare survival curves between groups.

Nasopharyngeal neoplasms refer to abnormal growths or tumors in the nasopharynx, which is the upper part of the pharynx (throat) behind the nose. These growths can be benign (non-cancerous) or malignant (cancerous).

Malignant nasopharyngeal neoplasms are often referred to as nasopharyngeal carcinoma or cancer. There are different types of nasopharyngeal carcinomas, including keratinizing squamous cell carcinoma, non-keratinizing carcinoma, and basaloid squamous cell carcinoma.

The risk factors for developing nasopharyngeal neoplasms include exposure to the Epstein-Barr virus (EBV), consumption of certain foods, smoking, and genetic factors. Symptoms may include a lump in the neck, nosebleeds, hearing loss, ringing in the ears, and difficulty swallowing or speaking. Treatment options depend on the type, size, and stage of the neoplasm and may include surgery, radiation therapy, chemotherapy, or a combination of these treatments.

Thyroid neoplasms refer to abnormal growths or tumors in the thyroid gland, which can be benign (non-cancerous) or malignant (cancerous). These growths can vary in size and may cause a noticeable lump or nodule in the neck. Thyroid neoplasms can also affect the function of the thyroid gland, leading to hormonal imbalances and related symptoms. The exact causes of thyroid neoplasms are not fully understood, but risk factors include radiation exposure, family history, and certain genetic conditions. It is important to note that most thyroid nodules are benign, but a proper medical evaluation is necessary to determine the nature of the growth and develop an appropriate treatment plan.

Breast neoplasms refer to abnormal growths in the breast tissue that can be benign or malignant. Benign breast neoplasms are non-cancerous tumors or growths, while malignant breast neoplasms are cancerous tumors that can invade surrounding tissues and spread to other parts of the body.

Breast neoplasms can arise from different types of cells in the breast, including milk ducts, milk sacs (lobules), or connective tissue. The most common type of breast cancer is ductal carcinoma, which starts in the milk ducts and can spread to other parts of the breast and nearby structures.

Breast neoplasms are usually detected through screening methods such as mammography, ultrasound, or MRI, or through self-examination or clinical examination. Treatment options for breast neoplasms depend on several factors, including the type and stage of the tumor, the patient's age and overall health, and personal preferences. Treatment may include surgery, radiation therapy, chemotherapy, hormone therapy, or targeted therapy.

Disease-free survival (DFS) is a term used in medical research and clinical practice, particularly in the field of oncology. It refers to the length of time after primary treatment for a cancer during which no evidence of the disease can be found. This means that the patient shows no signs or symptoms of the cancer, and any imaging studies or other tests do not reveal any tumors or other indications of the disease.

DFS is often used as an important endpoint in clinical trials to evaluate the effectiveness of different treatments for cancer. By measuring the length of time until the cancer recurs or a new cancer develops, researchers can get a better sense of how well a particular treatment is working and whether it is improving patient outcomes.

It's important to note that DFS is not the same as overall survival (OS), which refers to the length of time from primary treatment until death from any cause. While DFS can provide valuable information about the effectiveness of cancer treatments, it does not necessarily reflect the impact of those treatments on patients' overall survival.

'Tumor cells, cultured' refers to the process of removing cancerous cells from a tumor and growing them in controlled laboratory conditions. This is typically done by isolating the tumor cells from a patient's tissue sample, then placing them in a nutrient-rich environment that promotes their growth and multiplication.

The resulting cultured tumor cells can be used for various research purposes, including the study of cancer biology, drug development, and toxicity testing. They provide a valuable tool for researchers to better understand the behavior and characteristics of cancer cells outside of the human body, which can lead to the development of more effective cancer treatments.

It is important to note that cultured tumor cells may not always behave exactly the same way as they do in the human body, so findings from cell culture studies must be validated through further research, such as animal models or clinical trials.

Messenger RNA (mRNA) is a type of RNA (ribonucleic acid) that carries genetic information copied from DNA in the form of a series of three-base code "words," each of which specifies a particular amino acid. This information is used by the cell's machinery to construct proteins, a process known as translation. After being transcribed from DNA, mRNA travels out of the nucleus to the ribosomes in the cytoplasm where protein synthesis occurs. Once the protein has been synthesized, the mRNA may be degraded and recycled. Post-transcriptional modifications can also occur to mRNA, such as alternative splicing and addition of a 5' cap and a poly(A) tail, which can affect its stability, localization, and translation efficiency.

Lung neoplasms refer to abnormal growths or tumors in the lung tissue. These tumors can be benign (non-cancerous) or malignant (cancerous). Malignant lung neoplasms are further classified into two main types: small cell lung carcinoma and non-small cell lung carcinoma. Lung neoplasms can cause symptoms such as cough, chest pain, shortness of breath, and weight loss. They are often caused by smoking or exposure to secondhand smoke, but can also occur due to genetic factors, radiation exposure, and other environmental carcinogens. Early detection and treatment of lung neoplasms is crucial for improving outcomes and survival rates.

Loss of Heterozygosity (LOH) is a term used in genetics to describe the loss of one copy of a gene or a segment of a chromosome, where there was previously a pair of different genes or chromosomal segments (heterozygous). This can occur due to various genetic events such as mutation, deletion, or mitotic recombination.

LOH is often associated with the development of cancer, as it can lead to the loss of tumor suppressor genes, which normally help to regulate cell growth and division. When both copies of a tumor suppressor gene are lost or inactivated, it can result in uncontrolled cell growth and the formation of a tumor.

In medical terms, LOH is used as a biomarker for cancer susceptibility, progression, and prognosis. It can also be used to identify individuals who may be at increased risk for certain types of cancer, or to monitor patients for signs of cancer recurrence.

Mucoepidermoid carcinoma is a type of cancer that develops in the salivary glands or, less commonly, in other areas such as the lungs or skin. It is called "mucoepidermoid" because it contains two types of cells: mucus-secreting cells and squamous (or epidermoid) cells.

Mucoepidermoid carcinomas can vary in their behavior, ranging from low-grade tumors that grow slowly and rarely spread to other parts of the body, to high-grade tumors that are aggressive and can metastasize. The treatment and prognosis for mucoepidermoid carcinoma depend on several factors, including the grade and stage of the tumor, as well as the patient's overall health.

It is important to note that while I strive to provide accurate and up-to-date information, this definition may not capture all the nuances of this medical condition. Therefore, it is always best to consult with a healthcare professional for medical advice.

DNA Mutational Analysis is a laboratory test used to identify genetic variations or changes (mutations) in the DNA sequence of a gene. This type of analysis can be used to diagnose genetic disorders, predict the risk of developing certain diseases, determine the most effective treatment for cancer, or assess the likelihood of passing on an inherited condition to offspring.

The test involves extracting DNA from a patient's sample (such as blood, saliva, or tissue), amplifying specific regions of interest using polymerase chain reaction (PCR), and then sequencing those regions to determine the precise order of nucleotide bases in the DNA molecule. The resulting sequence is then compared to reference sequences to identify any variations or mutations that may be present.

DNA Mutational Analysis can detect a wide range of genetic changes, including single-nucleotide polymorphisms (SNPs), insertions, deletions, duplications, and rearrangements. The test is often used in conjunction with other diagnostic tests and clinical evaluations to provide a comprehensive assessment of a patient's genetic profile.

It is important to note that not all mutations are pathogenic or associated with disease, and the interpretation of DNA Mutational Analysis results requires careful consideration of the patient's medical history, family history, and other relevant factors.

The Mitotic Index (MI) is a measure of cell proliferation that reflects the percentage of cells in a population or sample that are undergoing mitosis, which is the process of cell division. It is often expressed as the number of mitotic figures (dividing cells) per 100 or 1,000 cells counted in a microscopic field. The Mitotic Index is used in various fields, including pathology and research, to assess the growth fraction of cells in tissues or cultures, and to monitor the effects of treatments that affect cell division, such as chemotherapy or radiation therapy.

Oligonucleotide Array Sequence Analysis is a type of microarray analysis that allows for the simultaneous measurement of the expression levels of thousands of genes in a single sample. In this technique, oligonucleotides (short DNA sequences) are attached to a solid support, such as a glass slide, in a specific pattern. These oligonucleotides are designed to be complementary to specific target mRNA sequences from the sample being analyzed.

During the analysis, labeled RNA or cDNA from the sample is hybridized to the oligonucleotide array. The level of hybridization is then measured and used to determine the relative abundance of each target sequence in the sample. This information can be used to identify differences in gene expression between samples, which can help researchers understand the underlying biological processes involved in various diseases or developmental stages.

It's important to note that this technique requires specialized equipment and bioinformatics tools for data analysis, as well as careful experimental design and validation to ensure accurate and reproducible results.

Uterine cervical neoplasms, also known as cervical cancer or cervical dysplasia, refer to abnormal growths or lesions on the lining of the cervix that have the potential to become cancerous. These growths are usually caused by human papillomavirus (HPV) infection and can be detected through routine Pap smears.

Cervical neoplasms are classified into different grades based on their level of severity, ranging from mild dysplasia (CIN I) to severe dysplasia or carcinoma in situ (CIN III). In some cases, cervical neoplasms may progress to invasive cancer if left untreated.

Risk factors for developing cervical neoplasms include early sexual activity, multiple sexual partners, smoking, and a weakened immune system. Regular Pap smears and HPV testing are recommended for early detection and prevention of cervical cancer.

A "mixed tumor, mesodermal" is not a widely recognized or currently used medical term in pathology. However, based on the context, it may refer to a type of tumor that contains a mixture of different cell types derived from the mesoderm, one of the three primary germ layers during embryonic development.

In general, a mixed tumor is a tumor composed of more than one type of tissue or cell type. In the context of soft tissue tumors, a "mixed tumor" may refer to a tumor with elements of both epithelial and mesenchymal differentiation, such as a pleomorphic adenoma.

However, in the context of mesodermal tissues, mixed tumors are not typically used to describe soft tissue tumors. Instead, the term "mixed" is more commonly used in the classification of certain types of ovarian tumors that contain both epithelial and mesenchymal elements, such as a Brenner tumor or a mullerian mixed tumor.

Therefore, it's important to provide more context or specify the body site when using the term "mixed tumor, mesodermal" to ensure accurate communication and understanding.

Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a laboratory technique used in molecular biology to amplify and detect specific DNA sequences. This technique is particularly useful for the detection and quantification of RNA viruses, as well as for the analysis of gene expression.

The process involves two main steps: reverse transcription and polymerase chain reaction (PCR). In the first step, reverse transcriptase enzyme is used to convert RNA into complementary DNA (cDNA) by reading the template provided by the RNA molecule. This cDNA then serves as a template for the PCR amplification step.

In the second step, the PCR reaction uses two primers that flank the target DNA sequence and a thermostable polymerase enzyme to repeatedly copy the targeted cDNA sequence. The reaction mixture is heated and cooled in cycles, allowing the primers to anneal to the template, and the polymerase to extend the new strand. This results in exponential amplification of the target DNA sequence, making it possible to detect even small amounts of RNA or cDNA.

RT-PCR is a sensitive and specific technique that has many applications in medical research and diagnostics, including the detection of viruses such as HIV, hepatitis C virus, and SARS-CoV-2 (the virus that causes COVID-19). It can also be used to study gene expression, identify genetic mutations, and diagnose genetic disorders.

Head and neck neoplasms refer to abnormal growths or tumors in the head and neck region, which can be benign (non-cancerous) or malignant (cancerous). These tumors can develop in various sites, including the oral cavity, nasopharynx, oropharynx, larynx, hypopharynx, paranasal sinuses, salivary glands, and thyroid gland.

Benign neoplasms are slow-growing and generally do not spread to other parts of the body. However, they can still cause problems if they grow large enough to press on surrounding tissues or structures. Malignant neoplasms, on the other hand, can invade nearby tissues and organs and may also metastasize (spread) to other parts of the body.

Head and neck neoplasms can have various symptoms depending on their location and size. Common symptoms include difficulty swallowing, speaking, or breathing; pain in the mouth, throat, or ears; persistent coughing or hoarseness; and swelling or lumps in the neck or face. Early detection and treatment of head and neck neoplasms are crucial for improving outcomes and reducing the risk of complications.

Tumor suppressor genes are a type of gene that helps to regulate and prevent cells from growing and dividing too rapidly or in an uncontrolled manner. They play a critical role in preventing the formation of tumors and cancer. When functioning properly, tumor suppressor genes help to repair damaged DNA, control the cell cycle, and trigger programmed cell death (apoptosis) when necessary. However, when these genes are mutated or altered, they can lose their ability to function correctly, leading to uncontrolled cell growth and the development of tumors. Examples of tumor suppressor genes include TP53, BRCA1, and BRCA2.

The Kaplan-Meier estimate is a statistical method used to calculate the survival probability over time in a population. It is commonly used in medical research to analyze time-to-event data, such as the time until a patient experiences a specific event like disease progression or death. The Kaplan-Meier estimate takes into account censored data, which occurs when some individuals are lost to follow-up before experiencing the event of interest.

The method involves constructing a survival curve that shows the proportion of subjects still surviving at different time points. At each time point, the survival probability is calculated as the product of the conditional probabilities of surviving from one time point to the next. The Kaplan-Meier estimate provides an unbiased and consistent estimator of the survival function, even when censoring is present.

In summary, the Kaplan-Meier estimate is a crucial tool in medical research for analyzing time-to-event data and estimating survival probabilities over time while accounting for censored observations.

Treatment outcome is a term used to describe the result or effect of medical treatment on a patient's health status. It can be measured in various ways, such as through symptoms improvement, disease remission, reduced disability, improved quality of life, or survival rates. The treatment outcome helps healthcare providers evaluate the effectiveness of a particular treatment plan and make informed decisions about future care. It is also used in clinical research to compare the efficacy of different treatments and improve patient care.

Gene expression profiling is a laboratory technique used to measure the activity (expression) of thousands of genes at once. This technique allows researchers and clinicians to identify which genes are turned on or off in a particular cell, tissue, or organism under specific conditions, such as during health, disease, development, or in response to various treatments.

The process typically involves isolating RNA from the cells or tissues of interest, converting it into complementary DNA (cDNA), and then using microarray or high-throughput sequencing technologies to determine which genes are expressed and at what levels. The resulting data can be used to identify patterns of gene expression that are associated with specific biological states or processes, providing valuable insights into the underlying molecular mechanisms of diseases and potential targets for therapeutic intervention.

In recent years, gene expression profiling has become an essential tool in various fields, including cancer research, drug discovery, and personalized medicine, where it is used to identify biomarkers of disease, predict patient outcomes, and guide treatment decisions.

Embryonal carcinoma is a rare and aggressive type of cancer that arises from primitive germ cells. It typically occurs in the gonads (ovaries or testicles), but can also occur in other areas of the body such as the mediastinum, retroperitoneum, or sacrococcygeal region.

Embryonal carcinoma is called "embryonal" because the cancerous cells resemble those found in an embryo during early stages of development. These cells are capable of differentiating into various cell types, which can lead to a mix of cell types within the tumor.

Embryonal carcinoma is a highly malignant tumor that tends to grow and spread quickly. It can metastasize to other parts of the body, including the lungs, liver, brain, and bones. Treatment typically involves surgical removal of the tumor, followed by chemotherapy and/or radiation therapy to kill any remaining cancer cells.

Prognosis for embryonal carcinoma depends on several factors, including the stage of the disease at diagnosis, the location of the tumor, and the patient's overall health. In general, this type of cancer has a poor prognosis, with a high risk of recurrence even after treatment.

Esophageal neoplasms refer to abnormal growths in the tissue of the esophagus, which is the muscular tube that connects the throat to the stomach. These growths can be benign (non-cancerous) or malignant (cancerous). Malignant esophageal neoplasms are typically classified as either squamous cell carcinomas or adenocarcinomas, depending on the type of cell from which they originate.

Esophageal cancer is a serious and often life-threatening condition that can cause symptoms such as difficulty swallowing, chest pain, weight loss, and coughing. Risk factors for esophageal neoplasms include smoking, heavy alcohol consumption, gastroesophageal reflux disease (GERD), and Barrett's esophagus. Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

A mouth neoplasm refers to an abnormal growth or tumor in the oral cavity, which can be benign (non-cancerous) or malignant (cancerous). Malignant mouth neoplasms are also known as oral cancer. They can develop on the lips, gums, tongue, roof and floor of the mouth, inside the cheeks, and in the oropharynx (the middle part of the throat at the back of the mouth).

Mouth neoplasms can have various causes, including genetic factors, tobacco use, alcohol consumption, and infection with human papillomavirus (HPV). Symptoms may include a lump or thickening in the oral soft tissues, white or red patches, persistent mouth sores, difficulty swallowing or speaking, and numbness in the mouth. Early detection and treatment of mouth neoplasms are crucial for improving outcomes and preventing complications.

Merkel cell carcinoma (MCC) is a rare and aggressive type of skin cancer that originates from the uncontrolled growth of Merkel cells, which are specialized nerve cells found in the top layer of the skin (epidermis). These cells are responsible for touch sensation. MCC typically presents as a painless, firm, rapidly growing nodule or mass, often on sun-exposed areas such as the head, neck, and arms of older adults.

The primary risk factors for Merkel cell carcinoma include:

1. Exposure to ultraviolet (UV) radiation from sunlight or tanning beds
2. Advanced age (most commonly occurs in people over 50)
3. A weakened immune system due to conditions like HIV/AIDS, organ transplantation, or long-term use of immunosuppressive medications
4. History of other types of skin cancer, such as melanoma or basal cell carcinoma
5. Fair skin and light eye color

MCC is considered an aggressive cancer because it can spread quickly to nearby lymph nodes and other parts of the body (metastasize). The major prognostic factor for MCC is the presence or absence of lymph node involvement at the time of diagnosis. Early detection and treatment are crucial for improving outcomes.

Standard treatments for Merkel cell carcinoma include surgical excision, radiation therapy, and chemotherapy. Immunotherapy with drugs like avelumab has also shown promising results in treating advanced stages of MCC. Regular follow-up care is essential to monitor for recurrence or metastasis.

Progesterone receptors (PRs) are a type of nuclear receptor proteins that are expressed in the nucleus of certain cells and play a crucial role in the regulation of various physiological processes, including the menstrual cycle, embryo implantation, and maintenance of pregnancy. These receptors bind to the steroid hormone progesterone, which is produced primarily in the ovaries during the second half of the menstrual cycle and during pregnancy.

Once progesterone binds to the PRs, it triggers a series of molecular events that lead to changes in gene expression, ultimately resulting in the modulation of various cellular functions. Progesterone receptors exist in two main isoforms, PR-A and PR-B, which differ in their size, structure, and transcriptional activity. Both isoforms are expressed in a variety of tissues, including the female reproductive tract, breast, brain, and bone.

Abnormalities in progesterone receptor expression or function have been implicated in several pathological conditions, such as uterine fibroids, endometriosis, breast cancer, and osteoporosis. Therefore, understanding the molecular mechanisms underlying PR signaling is essential for developing novel therapeutic strategies to treat these disorders.

Carcinoma, ductal refers to a type of cancer that begins in the milk ducts (tubes that carry milk from the breast to the nipple). It is most commonly found in the breast and is often referred to as "invasive ductal carcinoma" when it has spread beyond the ducts into the surrounding breast tissue. Ductal carcinoma can also occur in other organs, such as the pancreas, where it is called "pancreatic ductal adenocarcinoma." This type of cancer is usually aggressive and can metastasize (spread) to other parts of the body.

Disease progression is the worsening or advancement of a medical condition over time. It refers to the natural course of a disease, including its development, the severity of symptoms and complications, and the impact on the patient's overall health and quality of life. Understanding disease progression is important for developing appropriate treatment plans, monitoring response to therapy, and predicting outcomes.

The rate of disease progression can vary widely depending on the type of medical condition, individual patient factors, and the effectiveness of treatment. Some diseases may progress rapidly over a short period of time, while others may progress more slowly over many years. In some cases, disease progression may be slowed or even halted with appropriate medical interventions, while in other cases, the progression may be inevitable and irreversible.

In clinical practice, healthcare providers closely monitor disease progression through regular assessments, imaging studies, and laboratory tests. This information is used to guide treatment decisions and adjust care plans as needed to optimize patient outcomes and improve quality of life.

Microsatellite repeats, also known as short tandem repeats (STRs), are repetitive DNA sequences made up of units of 1-6 base pairs that are repeated in a head-to-tail manner. These repeats are spread throughout the human genome and are highly polymorphic, meaning they can have different numbers of repeat units in different individuals.

Microsatellites are useful as genetic markers because of their high degree of variability. They are commonly used in forensic science to identify individuals, in genealogy to trace ancestry, and in medical research to study genetic diseases and disorders. Mutations in microsatellite repeats have been associated with various neurological conditions, including Huntington's disease and fragile X syndrome.

CA-125 antigen is a type of protein that is found on the surface of many ovarian cancer cells and is often used as a tumor marker to monitor the effectiveness of treatment and to detect recurrence of ovarian cancer. Elevated levels of CA-125 may also be present in other types of cancer, as well as nonmalignant conditions such as endometriosis, pelvic inflammatory disease, and cirrhosis. It is important to note that while CA-125 can be a useful tool in managing ovarian cancer, it is not specific to this type of cancer and should be used in conjunction with other diagnostic tests and clinical evaluations.

Tumor-associated carbohydrate antigens (TACAs) are a type of tumor antigen that are expressed on the surface of cancer cells. These antigens are abnormal forms of carbohydrates, also known as glycans, which are attached to proteins and lipids on the cell surface.

TACAs are often overexpressed or expressed in a different form on cancer cells compared to normal cells. This makes them attractive targets for cancer immunotherapy because they can be recognized by the immune system as foreign and elicit an immune response. Some examples of TACAs include gangliosides, fucosylated glycans, and sialylated glycans.

Tumor-associated carbohydrate antigens have been studied as potential targets for cancer vaccines, antibody therapies, and other immunotherapeutic approaches. However, their use as targets for cancer therapy is still in the early stages of research and development.

Adrenocortical carcinoma (ACC) is a rare cancer that develops in the outer layer of the adrenal gland, known as the adrenal cortex. The adrenal glands are small hormone-producing glands located on top of each kidney. They produce important hormones such as cortisol, aldosterone, and sex steroids.

ACC is a malignant tumor that can invade surrounding tissues and organs and may metastasize (spread) to distant parts of the body. Symptoms of ACC depend on the size and location of the tumor and whether it produces excess hormones. Common symptoms include abdominal pain, a mass in the abdomen, weight loss, and weakness. Excessive production of hormones can lead to additional symptoms such as high blood pressure, Cushing's syndrome, virilization (excessive masculinization), or feminization.

The exact cause of ACC is not known, but genetic factors, exposure to certain chemicals, and radiation therapy may increase the risk of developing this cancer. Treatment options for ACC include surgery, chemotherapy, radiation therapy, and targeted therapy. The prognosis for ACC varies depending on the stage and extent of the disease at diagnosis, as well as the patient's overall health.

Colonic neoplasms refer to abnormal growths in the large intestine, also known as the colon. These growths can be benign (non-cancerous) or malignant (cancerous). The two most common types of colonic neoplasms are adenomas and carcinomas.

Adenomas are benign tumors that can develop into cancer over time if left untreated. They are often found during routine colonoscopies and can be removed during the procedure.

Carcinomas, on the other hand, are malignant tumors that invade surrounding tissues and can spread to other parts of the body. Colorectal cancer is the third leading cause of cancer-related deaths in the United States, and colonic neoplasms are a significant risk factor for developing this type of cancer.

Regular screenings for colonic neoplasms are recommended for individuals over the age of 50 or those with a family history of colorectal cancer or other risk factors. Early detection and removal of colonic neoplasms can significantly reduce the risk of developing colorectal cancer.

Carcinoma, verrucous is a type of slow-growing, well-differentiated squamous cell carcinoma that has a exophytic, papillary, and warty appearance. It typically occurs in the oral cavity, larynx, and genital regions. The tumor often has a long clinical course and is locally invasive but has low potential for metastasis.

It's also known as Ackerman's tumor or Buschke-Lowenstein tumor when it occurs in the genital region. It can be caused by long-standing irritation, chronic inflammation, or infection with certain types of human papillomavirus (HPV). The diagnosis is usually made through a biopsy and imaging studies may be used to determine the extent of the tumor. Treatment typically involves surgical excision, but radiation therapy and chemotherapy may also be used in some cases.

Carcinoma, signet ring cell is a type of adenocarcinoma, which is a cancer that begins in glandular cells. In signet ring cell carcinoma, the cancer cells have a characteristic appearance when viewed under a microscope. They contain large amounts of mucin, a substance that causes the nucleus of the cell to be pushed to one side, giving the cell a crescent or "signet ring" shape.

Signet ring cell carcinoma can occur in various organs, including the stomach, colon, rectum, and breast. It is often aggressive and has a poor prognosis, as it tends to grow and spread quickly. Treatment options may include surgery, chemotherapy, and radiation therapy, depending on the location and extent of the cancer.

Estrogen receptors (ERs) are a type of nuclear receptor protein that are expressed in various tissues and cells throughout the body. They play a critical role in the regulation of gene expression and cellular responses to the hormone estrogen. There are two main subtypes of ERs, ERα and ERβ, which have distinct molecular structures, expression patterns, and functions.

ERs function as transcription factors that bind to specific DNA sequences called estrogen response elements (EREs) in the promoter regions of target genes. When estrogen binds to the ER, it causes a conformational change in the receptor that allows it to recruit co-activator proteins and initiate transcription of the target gene. This process can lead to a variety of cellular responses, including changes in cell growth, differentiation, and metabolism.

Estrogen receptors are involved in a wide range of physiological processes, including the development and maintenance of female reproductive tissues, bone homeostasis, cardiovascular function, and cognitive function. They have also been implicated in various pathological conditions, such as breast cancer, endometrial cancer, and osteoporosis. As a result, ERs are an important target for therapeutic interventions in these diseases.

Tumor suppressor proteins are a type of regulatory protein that helps control the cell cycle and prevent cells from dividing and growing in an uncontrolled manner. They work to inhibit tumor growth by preventing the formation of tumors or slowing down their progression. These proteins can repair damaged DNA, regulate gene expression, and initiate programmed cell death (apoptosis) if the damage is too severe for repair.

Mutations in tumor suppressor genes, which provide the code for these proteins, can lead to a decrease or loss of function in the resulting protein. This can result in uncontrolled cell growth and division, leading to the formation of tumors and cancer. Examples of tumor suppressor proteins include p53, Rb (retinoblastoma), and BRCA1/2.

Neoplasm metastasis is the spread of cancer cells from the primary site (where the original or primary tumor formed) to other places in the body. This happens when cancer cells break away from the original (primary) tumor and enter the bloodstream or lymphatic system. The cancer cells can then travel to other parts of the body and form new tumors, called secondary tumors or metastases.

Metastasis is a key feature of malignant neoplasms (cancers), and it is one of the main ways that cancer can cause harm in the body. The metastatic tumors may continue to grow and may cause damage to the organs and tissues where they are located. They can also release additional cancer cells into the bloodstream or lymphatic system, leading to further spread of the cancer.

The metastatic tumors are named based on the location where they are found, as well as the type of primary cancer. For example, if a patient has a primary lung cancer that has metastasized to the liver, the metastatic tumor would be called a liver metastasis from lung cancer.

It is important to note that the presence of metastases can significantly affect a person's prognosis and treatment options. In general, metastatic cancer is more difficult to treat than cancer that has not spread beyond its original site. However, there are many factors that can influence a person's prognosis and response to treatment, so it is important for each individual to discuss their specific situation with their healthcare team.

Nuclear proteins are a category of proteins that are primarily found in the nucleus of a eukaryotic cell. They play crucial roles in various nuclear functions, such as DNA replication, transcription, repair, and RNA processing. This group includes structural proteins like lamins, which form the nuclear lamina, and regulatory proteins, such as histones and transcription factors, that are involved in gene expression. Nuclear localization signals (NLS) often help target these proteins to the nucleus by interacting with importin proteins during active transport across the nuclear membrane.

Urinary Bladder Neoplasms are abnormal growths or tumors in the urinary bladder, which can be benign (non-cancerous) or malignant (cancerous). Malignant neoplasms can be further classified into various types of bladder cancer, such as urothelial carcinoma, squamous cell carcinoma, and adenocarcinoma. These malignant tumors often invade surrounding tissues and organs, potentially spreading to other parts of the body (metastasis), which can lead to serious health consequences if not detected and treated promptly and effectively.

Human chromosome pair 10 refers to a group of genetic materials that are present in every cell of the human body. Chromosomes are thread-like structures that carry our genes and are located in the nucleus of most cells. They come in pairs, with one set inherited from each parent.

Chromosome pair 10 is one of the 22 autosomal chromosome pairs, meaning they contain genes that are not related to sex determination. Each member of chromosome pair 10 is a single, long DNA molecule that contains thousands of genes and other genetic material.

Chromosome pair 10 is responsible for carrying genetic information that influences various traits and functions in the human body. Some of the genes located on chromosome pair 10 are associated with certain medical conditions, such as hereditary breast and ovarian cancer syndrome, neurofibromatosis type 1, and Waardenburg syndrome type 2A.

It's important to note that while chromosomes carry genetic information, not all variations in the DNA sequence will result in a change in phenotype or function. Some variations may have no effect at all, while others may lead to changes in how proteins are made and function, potentially leading to disease or other health issues.

Stomach neoplasms refer to abnormal growths in the stomach that can be benign or malignant. They include a wide range of conditions such as:

1. Gastric adenomas: These are benign tumors that develop from glandular cells in the stomach lining.
2. Gastrointestinal stromal tumors (GISTs): These are rare tumors that can be found in the stomach and other parts of the digestive tract. They originate from the stem cells in the wall of the digestive tract.
3. Leiomyomas: These are benign tumors that develop from smooth muscle cells in the stomach wall.
4. Lipomas: These are benign tumors that develop from fat cells in the stomach wall.
5. Neuroendocrine tumors (NETs): These are tumors that develop from the neuroendocrine cells in the stomach lining. They can be benign or malignant.
6. Gastric carcinomas: These are malignant tumors that develop from the glandular cells in the stomach lining. They are the most common type of stomach neoplasm and include adenocarcinomas, signet ring cell carcinomas, and others.
7. Lymphomas: These are malignant tumors that develop from the immune cells in the stomach wall.

Stomach neoplasms can cause various symptoms such as abdominal pain, nausea, vomiting, weight loss, and difficulty swallowing. The diagnosis of stomach neoplasms usually involves a combination of imaging tests, endoscopy, and biopsy. Treatment options depend on the type and stage of the neoplasm and may include surgery, chemotherapy, radiation therapy, or targeted therapy.

Skin neoplasms refer to abnormal growths or tumors in the skin that can be benign (non-cancerous) or malignant (cancerous). They result from uncontrolled multiplication of skin cells, which can form various types of lesions. These growths may appear as lumps, bumps, sores, patches, or discolored areas on the skin.

Benign skin neoplasms include conditions such as moles, warts, and seborrheic keratoses, while malignant skin neoplasms are primarily classified into melanoma, squamous cell carcinoma, and basal cell carcinoma. These three types of cancerous skin growths are collectively known as non-melanoma skin cancers (NMSCs). Melanoma is the most aggressive and dangerous form of skin cancer, while NMSCs tend to be less invasive but more common.

It's essential to monitor any changes in existing skin lesions or the appearance of new growths and consult a healthcare professional for proper evaluation and treatment if needed.

Lymph node excision is a surgical procedure in which one or more lymph nodes are removed from the body for the purpose of examination. This procedure is often conducted to help diagnose or stage various types of cancer, as malignant cells may spread to the lymphatic system and eventually accumulate within nearby lymph nodes.

During a lymph node excision, an incision is made in the skin overlying the affected lymph node(s). The surgeon carefully dissects the tissue surrounding the lymph node(s) to isolate them from adjacent structures before removing them. In some cases, a sentinel lymph node biopsy may be performed instead, where only the sentinel lymph node (the first lymph node to which cancer cells are likely to spread) is removed and examined.

The excised lymph nodes are then sent to a laboratory for histopathological examination, which involves staining and microscopic evaluation of the tissue to determine whether it contains any malignant cells. The results of this examination can help guide further treatment decisions and provide valuable prognostic information.

Follow-up studies are a type of longitudinal research that involve repeated observations or measurements of the same variables over a period of time, in order to understand their long-term effects or outcomes. In medical context, follow-up studies are often used to evaluate the safety and efficacy of medical treatments, interventions, or procedures.

In a typical follow-up study, a group of individuals (called a cohort) who have received a particular treatment or intervention are identified and then followed over time through periodic assessments or data collection. The data collected may include information on clinical outcomes, adverse events, changes in symptoms or functional status, and other relevant measures.

The results of follow-up studies can provide important insights into the long-term benefits and risks of medical interventions, as well as help to identify factors that may influence treatment effectiveness or patient outcomes. However, it is important to note that follow-up studies can be subject to various biases and limitations, such as loss to follow-up, recall bias, and changes in clinical practice over time, which must be carefully considered when interpreting the results.

A case-control study is an observational research design used to identify risk factors or causes of a disease or health outcome. In this type of study, individuals with the disease or condition (cases) are compared with similar individuals who do not have the disease or condition (controls). The exposure history or other characteristics of interest are then compared between the two groups to determine if there is an association between the exposure and the disease.

Case-control studies are often used when it is not feasible or ethical to conduct a randomized controlled trial, as they can provide valuable insights into potential causes of diseases or health outcomes in a relatively short period of time and at a lower cost than other study designs. However, because case-control studies rely on retrospective data collection, they are subject to biases such as recall bias and selection bias, which can affect the validity of the results. Therefore, it is important to carefully design and conduct case-control studies to minimize these potential sources of bias.

Gene expression is the process by which the information encoded in a gene is used to synthesize a functional gene product, such as a protein or RNA molecule. This process involves several steps: transcription, RNA processing, and translation. During transcription, the genetic information in DNA is copied into a complementary RNA molecule, known as messenger RNA (mRNA). The mRNA then undergoes RNA processing, which includes adding a cap and tail to the mRNA and splicing out non-coding regions called introns. The resulting mature mRNA is then translated into a protein on ribosomes in the cytoplasm through the process of translation.

The regulation of gene expression is a complex and highly controlled process that allows cells to respond to changes in their environment, such as growth factors, hormones, and stress signals. This regulation can occur at various stages of gene expression, including transcriptional activation or repression, RNA processing, mRNA stability, and translation. Dysregulation of gene expression has been implicated in many diseases, including cancer, genetic disorders, and neurological conditions.

Cytoskeletal proteins are a type of structural proteins that form the cytoskeleton, which is the internal framework of cells. The cytoskeleton provides shape, support, and structure to the cell, and plays important roles in cell division, intracellular transport, and maintenance of cell shape and integrity.

There are three main types of cytoskeletal proteins: actin filaments, intermediate filaments, and microtubules. Actin filaments are thin, rod-like structures that are involved in muscle contraction, cell motility, and cell division. Intermediate filaments are thicker than actin filaments and provide structural support to the cell. Microtubules are hollow tubes that are involved in intracellular transport, cell division, and maintenance of cell shape.

Cytoskeletal proteins are composed of different subunits that polymerize to form filamentous structures. These proteins can be dynamically assembled and disassembled, allowing cells to change their shape and move. Mutations in cytoskeletal proteins have been linked to various human diseases, including cancer, neurological disorders, and muscular dystrophies.

Medical Definition:

"Risk factors" are any attribute, characteristic or exposure of an individual that increases the likelihood of developing a disease or injury. They can be divided into modifiable and non-modifiable risk factors. Modifiable risk factors are those that can be changed through lifestyle choices or medical treatment, while non-modifiable risk factors are inherent traits such as age, gender, or genetic predisposition. Examples of modifiable risk factors include smoking, alcohol consumption, physical inactivity, and unhealthy diet, while non-modifiable risk factors include age, sex, and family history. It is important to note that having a risk factor does not guarantee that a person will develop the disease, but rather indicates an increased susceptibility.

"Nude mice" is a term used in the field of laboratory research to describe a strain of mice that have been genetically engineered to lack a functional immune system. Specifically, nude mice lack a thymus gland and have a mutation in the FOXN1 gene, which results in a failure to develop a mature T-cell population. This means that they are unable to mount an effective immune response against foreign substances or organisms.

The name "nude" refers to the fact that these mice also have a lack of functional hair follicles, resulting in a hairless or partially hairless phenotype. This feature is actually a secondary consequence of the same genetic mutation that causes their immune deficiency.

Nude mice are commonly used in research because their weakened immune system makes them an ideal host for transplanted tumors, tissues, and cells from other species, including humans. This allows researchers to study the behavior of these foreign substances in a living organism without the complication of an immune response. However, it's important to note that because nude mice lack a functional immune system, they must be kept in sterile conditions and are more susceptible to infection than normal mice.

Carcinoma, large cell is a type of lung cancer that is characterized by the presence of large, abnormal-looking cells when viewed under a microscope. These cells have a large nucleus and a significant amount of cytoplasm. This type of lung cancer can be further divided into subtypes based on the appearance of the cells and the presence or absence of specific genetic mutations.

Large cell carcinoma is often aggressive and tends to grow and spread quickly. It is typically treated with a combination of surgery, chemotherapy, and/or radiation therapy. The prognosis for large cell carcinoma varies depending on the stage at diagnosis and the individual's overall health.

Lymph nodes are small, bean-shaped organs that are part of the immune system. They are found throughout the body, especially in the neck, armpits, groin, and abdomen. Lymph nodes filter lymph fluid, which carries waste and unwanted substances such as bacteria, viruses, and cancer cells. They contain white blood cells called lymphocytes that help fight infections and diseases by attacking and destroying the harmful substances found in the lymph fluid. When an infection or disease is present, lymph nodes may swell due to the increased number of immune cells and fluid accumulation as they work to fight off the invaders.

Sex cord-gonadal stromal tumors are a type of rare cancer that develops in the cells of the ovaries or testicles that produce hormones and help to form ova or sperm. These tumors can be benign (noncancerous) or malignant (cancerous), and they can occur in both males and females, although they are more common in females.

There are several subtypes of sex cord-gonadal stromal tumors, including granulosa cell tumors, thecomas, fibromas, Sertoli cell tumors, Leydig cell tumors, and gonadoblastomas. The symptoms and treatment options for these tumors depend on several factors, including the type and stage of the tumor, the patient's age and overall health, and whether the tumor is producing hormones.

Common symptoms of sex cord-gonadal stromal tumors may include abdominal pain or swelling, bloating, irregular menstrual periods, vaginal bleeding, or a feeling of fullness in the abdomen. In some cases, these tumors may produce hormones that can cause additional symptoms, such as breast tenderness, acne, or voice deepening.

Treatment for sex cord-gonadal stromal tumors typically involves surgery to remove the tumor and any affected tissue. Depending on the stage and type of the tumor, additional treatments such as chemotherapy or radiation therapy may also be recommended. Regular follow-up care is important to monitor for recurrence and manage any long-term effects of treatment.

Cadherins are a type of cell adhesion molecule that play a crucial role in the development and maintenance of intercellular junctions. They are transmembrane proteins that mediate calcium-dependent homophilic binding between adjacent cells, meaning that they bind to identical cadherin molecules on neighboring cells.

There are several types of cadherins, including classical cadherins, desmosomal cadherins, and protocadherins, each with distinct functions and localization in tissues. Classical cadherins, also known as type I cadherins, are the most well-studied and are essential for the formation of adherens junctions, which help to maintain cell-to-cell contact and tissue architecture.

Desmosomal cadherins, on the other hand, are critical for the formation and maintenance of desmosomes, which are specialized intercellular junctions that provide mechanical strength and stability to tissues. Protocadherins are a diverse family of cadherin-related proteins that have been implicated in various developmental processes, including neuronal connectivity and tissue patterning.

Mutations in cadherin genes have been associated with several human diseases, including cancer, neurological disorders, and heart defects. Therefore, understanding the structure, function, and regulation of cadherins is essential for elucidating their roles in health and disease.

Transcription factors are proteins that play a crucial role in regulating gene expression by controlling the transcription of DNA to messenger RNA (mRNA). They function by binding to specific DNA sequences, known as response elements, located in the promoter region or enhancer regions of target genes. This binding can either activate or repress the initiation of transcription, depending on the properties and interactions of the particular transcription factor. Transcription factors often act as part of a complex network of regulatory proteins that determine the precise spatiotemporal patterns of gene expression during development, differentiation, and homeostasis in an organism.

In 40% of cases, endometrioid tumors are found bilaterally. Endometrioid carcinoma can also arise in the endometrium. Grades 1 ... Endometrioid tumors are a class of tumor characterized by a resemblance to endometrium/ endometrial carcinoma, and over a third ... Carcinoma,+Endometrioid at the U.S. National Library of Medicine Medical Subject Headings (MeSH) "ACS :: What Is Endometrial ... Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN gene mutation profiles. PTEN mutations are more ...
Papillary serous carcinoma, clear cell carcinoma, and endometrioid carcinoma are the subtypes at the highest risk of recurrence ... Histologically, TCCE resembles endometrioid carcinoma and is distinct from other transitional cell carcinomas. In contrast to ... Some endometrioid adenocarcinomas have foci of mucinous carcinoma. The genetic mutations most commonly associated with ... The most frequent type of endometrial cancer is endometrioid carcinoma, which accounts for more than 80% of cases. Endometrial ...
Rahilly MA, Al-Nafussi A (1991). Uterus-like mass of the ovary associated with endometrioid carcinoma. Histopathology 18:549- ... ULM has also been reported associated to endometrial carcinoma and breast cancer. A clonal chromosome deletion 2p21 was found ...
Distinction of HGSC from high-grade endometrioid carcinoma is not always possible. The progression of HGSC may also be ... Technically a 'serous carcinoma' can occur anywhere on these membranes, but high-grade serous carcinoma is generally limited to ... "TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting ... High-grade serous carcinoma (HGSC) is a type of tumour that arises from the serous epithelial layer in the abdominopelvic ...
... is overexpressed in non-small cell lung cancer and human placenta and chorionic carcinoma cells. In breast cancer, loss of ... For example, MTA3 expression is downregulated in breast cancer and endometrioid adenocarcinomas. ... "The metastasis-associated genes MTA1 and MTA3 are abundantly expressed in human placenta and chorionic carcinoma cells". ...
"Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma". ...
Mutations in this gene have been associated with hepatocellular carcinoma, hepatoblastomas, ovarian endometrioid ... "AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1". Nat ... "Evaluation of AXIN1 and AXIN2 as targets of tankyrase inhibition in hepatocellular carcinoma cell lines". Scientific Reports. ...
Risk factors for development of EIN and the endometrioid type of endometrial carcinoma include exposure to estrogens without ... a precursor lesion to uterine endometrioid carcinoma". Cancer Res. 58 (15): 3254-8. PMID 9699651. Mutter GL, Boynton KA, Faquin ... Some cases of EIN are first detected as residual premalignant disease in women who already have carcinoma, whereas other EIN ... Hecht JL, Ince TA, Baak JP, Baker HE, Ogden MW, Mutter GL (March 2005). "Prediction of endometrial carcinoma by subjective ...
The other major subtypes within this group include high-grade serous, endometrioid, mucinous, and low-grade serous. The serous ... Ovarian clear-cell carcinoma, or clear-cell carcinoma of the ovary, also called ovarian clear-cell adenocarcinoma, is one of ... There are two subtypes of ovarian carcinoma - epithelial and nonepithelial; ovarian clear-cell carcinoma is an epithelial ... Ovarian clear-cell carcinoma often occurs as a pelvic mass that rarely appears bilaterally. The cells usually contain glycogen ...
"Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers ... Uterine clear-cell carcinoma is staged like other forms of endometrial carcinoma at time of surgery using the International ... Uterine clear-cell carcinoma (CC) is a rare form of endometrial cancer with distinct morphological features on pathology; it is ... Like uterine papillary serous carcinoma CC does not develop from endometrial hyperplasia and is not hormone sensitive, rather ...
15-30% of endometrioid carcinomas occur in individuals with carcinoma of the endometrium, and these patients have a better ... Endometrioid tumors account for approximately 20% of all ovarian cancers and are mostly malignant (endometroid carcinomas). ... ISBN 978-0-07-147257-9. Smedley H, Sikora K. Age as a prognostic factor in epithelial ovarian carcinoma. Br J Obstet Gynaecol ... Bakhru A, Liu JR, Lagstein A (2012). "A case of small cell carcinoma of the ovary hypercalcemic variant in a teenager". ...
Though mixed carcinomas can have any combination of cell types, mixed ovarian cancers are typically serous/endometrioid or ... Type I cancers are of low histological grade and include endometrioid, mucinous, and clear-cell carcinomas. Type II cancers are ... Low-grade serous carcinoma is less aggressive than high-grade serous carcinomas, though it does not typically respond well to ... More typically, ovarian squamous cell carcinomas are cervical metastases, areas of differentiation in an endometrioid tumor, or ...
... is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas". Cancer Res. 65 (6): 2162-9. ... protein is a biomarker for ovarian carcinoma". Cancer Res. 63 (13): 3695-700. PMID 12839961. Drapkin R, von Horsten HH, Lin Y, ... "Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas". ... Protein Is a Biomarker for Ovarian Carcinoma". Cancer Research. 63 (13): 3695-3700. PMID 12839961. Retrieved 2012-11-28. ...
... is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma". Int ...
Notably, the expression of mPRγ was significantly higher in endometrioid and clear cell carcinomas, which are closely related ... and carcinomas: while mPRα is expressed at significantly higher levels than the others, an increased expression of mPRβ has ... been noticed in mucinous carcinomas when compared to the other tumor types and normal tissues. ...
Unlike the more common low-grade endometrioid endometrial adenocarcinoma, uterine serous carcinoma does not develop from ... Serous carcinomas often have bulky peritoneal and omental metastases, and spread to the lymph nodes is frequent. Beginning in ... Uterine serous carcinoma is an uncommon form of endometrial cancer that typically arises in postmenopausal women. It is ... There is a 25% survival rate with a stage III serous carcinoma. Staging: Stage I - Tumour growth limited to ovaries. Stage II ...
Unlike the more common low-grade endometrioid endometrial adenocarcinoma, uterine serous carcinoma does not develop from ... Uterine papillary serous carcinoma is staged like other forms of endometrial carcinoma at time of surgery using the ... Uterine serous carcinoma is a malignant form of serous tumor that originates in the uterus. It is an uncommon form of ... In a recent study, about 60% of uterine serous carcinomas were found to overexpress the protein HER2/neu-the same one that is ...
... endometrioid, or clear cell carcinoma, Brenner tumor, granulosa cell tumor, stromal tumor, dysgerminoma, fibroma, or metastatic ... "A case of Meigs syndrome mimicking metastatic breast carcinoma". World Journal of Surgical Oncology. 7: 10. doi:10.1186/1477- ...
... as well as the more aggressive uterine papillary serous carcinoma and uterine clear-cell carcinoma. Malignant mixed Müllerian ... These include the common and readily treatable well-differentiated endometrioid adenocarcinoma, ... "Endometrial carcinoma: Clinical features, diagnosis, prognosis, and screening". www.uptodate.com. Retrieved 2021-09-18. " ... Uharcek P (October 2008). "Prognostic factors in endometrial carcinoma". The Journal of Obstetrics and Gynaecology Research. 34 ...
... endometrioid endometrial carcinoma), as well as pleomorphic adenoma. Metaplasia Dysplasia Barrett esophagus - a columnar cell ...
... carcinoma, pancreatic ductal MeSH C04.557.470.200.025.240 - carcinoma, endometrioid MeSH C04.557.470.200.025.255 - carcinoma, ... carcinoma, ehrlich tumor MeSH C04.557.470.200.220 - carcinoma, giant cell MeSH C04.557.470.200.240 - carcinoma in situ MeSH ... carcinoma, large cell MeSH C04.557.470.200.280 - carcinoma, lewis lung MeSH C04.557.470.200.300 - carcinoma, non-small-cell ... carcinoma, bronchogenic MeSH C04.588.894.797.520.230 - carcinoma, non-small-cell lung MeSH C04.588.894.797.520.235 - carcinoma ...
... renal cell carcinoma, testicular germ cell tumors, colorectal cancer, lung cancer, bladder cancer, endometrioid endometrial ... McNeish IA, Bell S, McKay T, Tenev T, Marani M, Lemoine NR (June 2003). "Expression of Smac/DIABLO in ovarian carcinoma cells ... So far, SMAC overexpression has been observed to oppose cancer progression in head and neck squamous cell carcinoma, ... hepatocellular carcinoma, Hodgkin lymphoma, breast cancer, glioblastoma, thyroid cancer, ...
... carcinoma, endometrioid MeSH C13.371.056.630.705.398 - granulosa cell tumor MeSH C13.371.056.630.705.464 - luteoma MeSH C13.371 ... carcinoma, endometrioid MeSH C13.371.820.800.418.685.398 - granulosa cell tumor MeSH C13.371.820.800.418.685.464 - luteoma MeSH ... carcinoma, endometrioid MeSH C13.371.820.800.418.875.200.374 - endometrial stromal tumors MeSH C13.371.820.800.418.875.200.374. ... carcinoma, renal cell MeSH C13.371.820.800.820.535.585 - wilms tumor MeSH C13.371.820.800.820.535.585.220 - denys-drash ...
... carcinoma, endometrioid MeSH C19.391.630.705.398 - granulosa cell tumor MeSH C19.391.630.705.464 - luteoma MeSH C19.391.630.705 ... carcinoma, islet cell MeSH C19.344.421.500.124 - gastrinoma MeSH C19.344.421.500.249 - glucagonoma MeSH C19.344.421.500.500 - ... adrenocortical carcinoma MeSH C19.344.400.500 - multiple endocrine neoplasia type 1 MeSH C19.344.400.505 - multiple endocrine ... adrenocortical carcinoma MeSH C19.053.347.500 - adrenal cortex neoplasms MeSH C19.053.347.500.500 - adrenocortical adenoma MeSH ...
Adenomyoma Myo-invasive endometrial endometrioid carcinoma (vs. stroma-poor adenomyosis) Low-grade endometrial stromal sarcoma ... However, both entities could coexist and the endometrial tissue within the myometrium could harbor endometrioid adenocarcinoma ...
... endometrioid) Clear cell adenocarcinoma Serous carcinoma Adenosquamous carcinoma Glassy cell carcinoma Adenoid cystic carcinoma ... Also called carcinoma in situ (CIS). The carcinoma has grown into the cervix, but has not spread beyond it (extension to the ... Adenoid basal carcinoma Small cell carcinoma Undifferentiated carcinoma Cancers can be histopathologically graded as follows: ... If the specimen is not satisfactory, a small loop biopsy or cone may be required.[citation needed] The carcinoma is confined to ...
... papillary renal cell carcinoma, papillary endometrioid carcinoma of the prostate, in thymic carcinomas, and in non-epithelial ... It can be present in: Thyroid neoplasms: It is a characteristic feature of papillary thyroid carcinoma, but has also been seen ... Breast carcinomas Vaginal, cervical and/or endometrial neoplasms Papillary neoplasms of several organs: papillary transitional ...
... her research team used genetically modified mice to mimic tumors that closely resembled human high-grade serous carcinomas. In ... Cho's laboratory developed a mouse model to research ovarian endometrioid adenocarcinoma. From 2013 to 2014, Cho served as ...
Carcinoma is confined to the corpus uteri itself. Stage II. Carcinoma involves the corpus and the cervix. Stage III. Carcinoma ... On histology, the tumors consist of adenocarcinoma (endometrioid, serous or clear cell) mixed with the malignant mesenchymal ( ... Carcinoma extends outside the true pelvis or involves the mucosa of the bladder or the rectum. A Cochrane review indicates ... As with endometrial carcinomas, the prognosis is influenced by the grade and type of the adenocarcinoma, being poorest with ...
October 2017). "Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a ... High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (ARIEL3) " at ClinicalTrials. ... double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma ( ...
According to urethroscopic and rectal palpation findings, six of the carcinomas were located centrally, 40 tumors were in the ... Fifty carcinomas that were partially to completely papillary in nature were examined. ... Usual carcinomas of the prostate proper can develop endometrioid structures that do not differ immunohistochemically from ... We conclude that a distinction between endometrioid carcinomas and tumors of prostatic ducts does not seem justified and that ...
Lynch Syndrome, Recurrent Uterine Corpus Carcinoma, Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage III ...
Grade 2 carcinoma is associated with pelvic lymph-node metastasis, depending on selected risk factors. Intraoperative ... the diagnostic precision of IOA in determining the need for surgical staging in grade 2 endometrioid endometrial carcinoma. Two ... IOA is an adequate tool to identify high-risk patients in grade 2 endometrial carcinoma. Myometrial invasion is the individual ... Endometrial carcinoma is the most common gynecologic malignancy in developed countries. ...
Predicting high-risk endometrioid carcinomas using proteins. Di Du, Wencai Ma, Melinda S. Yates, Tao Chen, Karen H. Lu, Yiling ... Keywords: RPPA; stage; protein; biomarker; endometrioid carcinoma. Received: September 14, 2017 Accepted: February 24, 2018 ... Background: The lethality of endometrioid endometrial cancer (EEC) is primarily attributable to advanced-stage diseases. We ...
A Sample to Insight biological explorationPresented by Dr. Jean-Noel Billaud, Ph.D., Principal Scientist, QIAGEN BioinformaticsOctober, 2015
Both clear cell ovarian carcinomas (CCC) and ovarian endometrioid carcinomas (EC) may arise from endometriosis and frequently ... Immunohistochemistry (IHC) for BAF250a expression was performed on 127 chemotherapy-naive ovarian carcinomas (33 CCC, 29 EC, ... and 65 high-grade serous ovarian carcinomas (HGSC)). Whole tumor lysates were prepared from frozen banked tumor samples and ... Both clear cell ovarian carcinomas (CCC) and ovarian endometrioid carcinomas (EC) may arise from endometriosis and frequently ...
Endometrioid Carcinomas. These cancer cells are typically very slow-growing and dont cause many symptoms. Because of that, a ... Mucinous Carcinomas. Younger women are at a much lower risk of developing this cancer than older ones are. In fact, women under ... Clear-cell Carcinomas. This type of ovarian cancer tends to produce symptoms at an earlier stage than other types of ovarian ... Serous Carcinomas. Serous tumors comprise over half of all epithelial ovarian tumors. Depending on how the cells look and act, ...
Spatial expression of the FGFR2b splice isoform and its prognostic significance in endometrioid endometrial carcinoma * ... Spatial expression of the FGFR2b splice isoform and its prognosticsignificance in endometrioid endometrial carcinoma (2022) ... Spatial expression of the FGFR2b splice isoform and its prognostic significance in endometrioid endometrial carcinoma. ...
Risk stratifications for endometrial carcinoma (EC) depend on histopathology and molecular pathology. Histopathological risk ... chromosomal instability and mutations for risk stratification in early-stage endometrioid endometrial carcinoma ...
In 40% of cases, endometrioid tumors are found bilaterally. Endometrioid carcinoma can also arise in the endometrium. Grades 1 ... Endometrioid tumors are a class of tumor characterized by a resemblance to endometrium/ endometrial carcinoma, and over a third ... Carcinoma,+Endometrioid at the U.S. National Library of Medicine Medical Subject Headings (MeSH) "ACS :: What Is Endometrial ... Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN gene mutation profiles. PTEN mutations are more ...
The role of adjuvant therapy in stage I grade 3 endometrioid endometrial carcinoma (EEC) is debatable. We sought to define the ... Risk Stratification of Stage I Grade 3 Endometrioid Endometrial Carcinoma in the Era of Molecular Classification. ... Risk Stratification of Stage I Grade 3 Endometrioid Endometrial Carcinoma in the Era of Mo ... Carcinoma Endometrioide; Neoplasias do Endométrio; Linfoma Folicular; Neoplasias Testiculares; Carcinoma Endometrioide/genética ...
... for 5-year relative survival in stage I-III grade 1-3 endometrioid endometrial carcinoma. In a subgroup analysis of stage I ... and age in stage I-III endometrioid endometrial carcinoma. In stage I, aneuploidy and grade 2 predicted lower relative survival ... and p53 are not independent prognostic factors for survival in endometrioid endometrial carcinoma FIGO stage I-III ... stage I-III grade 1-3 endometrioid endometrial carcinoma in 2006-2011. Histology, grade, stage, and age were prospectively ...
Most endometrial carcinomas are endometrioid adenocarcinomas. Adenoacanthomas (benign squamous components) and adenosquamous ... encoded search term (Endometrial Carcinoma) and Endometrial Carcinoma What to Read Next on Medscape ... Endometrial Carcinoma. Updated: Aug 22, 2023 * Author: William T Creasman, MD; Chief Editor: Leslie M Randall, MD, MAS, FACS ... Examination in a woman with suspected endometrial carcinoma includes the following:. * Pelvic examination: Findings may be ...
Endometrioid Adenocarcinoma, FIGO Grade 1. Home "> Gynecologic "> Uterus "> Endometrial Carcinoma "> Endometrioid ... Endometrioid Adenocarcinoma, FIGO Grade 1. High Quality Pathology Images of Gynecologic, Uterus, Endometrial Carcinoma. ... The diagnosis of endometrioid adenocarcinoma can also be made if there is extensive papillary pattern or infiltrative glands ...
Tumor cell plasticity in endometrioid carcinoma is regulated by neuronal membrane glycoprotein M6‑b. Shinya Kusumoto, Jun- ... Use of clinicopathological factors to predict prognosis of fertility‑sparing treatment for endometrial endometrioid carcinoma ... weighted imaging and apparent diffusion coefficient for renal clear cell carcinoma and non‑clear cell carcinoma. Xiaozhong Li, ... Carcinomatous meningitis from ovarian serous carcinoma: A case report. Eijiro Uchikura, Takeshi Fukuda, Kenji Imai, Makoto ...
Participant has non-epithelial carcinoma, clear-cell, mucinous, germ-cell, low-grade serous, or low-grade endometrioid ... A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma ... For Ovarian Carcinoma:. *Participant must have histologically documented, platinum resistant, advanced (metastatic and/or ... For Urothelial Carcinoma. *Participant must have histologically documented, advanced (metastatic and/or unresectable) ...
Endometrioid endometrial carcinoma (EEA) histological type was present in 89.07% of patients for both groups, with other types ... MRS, metabolic risk score; EEA, endometrioid endometrial carcinoma; LNM, lymph node metastasis. ... early-stage endometrioid endometrial carcinoma. Cancers (Basel). 11:18452019. View Article : Google Scholar : PubMed/NCBI ... Metabolic syndrome affects the long-term survival of patients with non-endometrioid carcinoma of the uterine corpus. Int J ...
Mixed Clear Cell and Endometrioid Carcinoma Arising in Parietal Endometriosis Gynecol Obstet Invest (October,2006) ... Hepatocellular Carcinoma with Foamy Histiocyte-Like Appearance: A Deceptively Clear Cell Carcinoma Appearing Variant Subject ... Hepatocellular Carcinoma with Foamy Histiocyte-Like Appearance: A Deceptively Clear Cell Carcinoma Appearing Variant. Case Rep ... it is difficult to distinguish this HCC variant from clear cell carcinoma or metastases of renal cell carcinoma. It is ...
Most ECs are endometrioid, serous, or clear cell carcinomas, or an admixture of histologies. Serous and clear ECs are ... At diagnosis, the majority of ECs are carcinomas of endometrioid, serous, or clear cell histologies, or an admixture of at ... Endometrial carcinomas can be classified into several histological subtypes including endometrioid and serous histologies. Over ... In the US, the majority of deaths from endometrial carcinoma are attributed to the serous and endometrioid subtypes. An ...
Issues in the Differential Diagnosis of Uterine Low-grade Endometrioid Carcinoma, Including Mixed Endometrial Carcinomas: ... Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the ... High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations. ... Pathologic Prognostic Factors in Endometrial Carcinoma (Other Than Tumor Type and Grade). Singh, Naveena; Hirschowitz, Lynn; ...
The main subtypes are serous, mucinous, endometrioid, and clear cell carcinomas. These types show significant differences in ... The mean value reported for CA-125 in mucinous carcinoma stage I is 44.2 U/mL, while stage II-IV is 176.7 U/mL. In another ... 6 Ricci F, Affatato R, Carrassa L, Damia G. Recent insights into mucinous ovarian carcinoma. Int J Mol Sci 2018; 19 (06) 1569 ... 6 Ricci F, Affatato R, Carrassa L, Damia G. Recent insights into mucinous ovarian carcinoma. Int J Mol Sci 2018; 19 (06) 1569 ...
The majority of BRCA-related OC is high-grade serous carcinoma (HGSC) (67%) and endometrioid carcinoma (12%) [8]. ... Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel ... Serous tubal intraepithelial carcinoma--an update. J. Obstet. Gynaecol. Res. 2015, 41, 6-11. [Google Scholar] [CrossRef][Green ... particularly for low-grade carcinoma [35]. At this time, hysterectomy at the time of RRBSO is not recommended in the Canadian ...
CRKL and CK2 β over Expression Are Independent Predictors of Patients Survival in Endometrioid Endometrial Carcinoma (Articles) ...
Endometrioid borderline tumors. Endometrioid tumors of the ovary are usually carcinomas, while borderline forms are very rare; ... Endometrioid BOTs, also called Atypical Proliferative Endometrioid Tumors (APET), account for the 0,2% of ovarian epithelial ... Epithelial ovarian carcinoma of low malignant potential. Eur J Obstet Gynecol Reprod Biol 66. 141. 145. ... Morice P Management and prognosis of endometrioid borderline tumors of the ovary. Surg Oncol. 2012. Sep;. 21. 3. 178. 84. ...
Results: The preoperative biopsies were all typical ovarian serous or endometrioid adenocarcinomas. Morphological features ... This study aims to describe the morphological features found in ovarian carcinoma after chemotherapy because these have not ... Methods: Histological sections were examined from 18 cases of ovarian carcinoma that had been treated by preoperative ... Aims: Traditionally, advanced stage ovarian carcinoma is treated by debulking surgery followed by chemotherapy. However, in ...
percentage of study population developing endometrioid carcinoma during a period of time (CMO:0001759). 20. 1. 25159026. Rat. ... Colorectal carcinoma resistance QTL 9. 2.97. 0.0024. intestine integrity trait (VT:0010554). benign colorectal tumor number ( ... Endometrial carcinoma susceptibility QTL3. 3.5. 0.003. uterus morphology trait (VT:0001120). ...
Case 6: endometrioid adenocarcinoma stage IbCase 6: endometrioid adenocarcinoma stage Ib ... Staging of endometrial carcinoma is based on the FIGO staging system, which is a surgical and pathological staging following ... Type II endometrial carcinoma. Type II (20%) arises in the setting of endometrial atrophy, in females between 65 to 75 years ... Ji M, Lu Y, Guo L, Feng F, Wan X, Xiang Y. Endometrial Carcinoma with Yolk Sac Tumor-Like Differentiation and Elevated Serum β- ...
Nonmelanotic skin cancer or carcinoma-in-situ of the cervix, or prostate or localized endometrioid endometrial cancer. ...
The intraepithelial carcinomas have been referred to as serous intraepithelial carcinomas (STICs) but our own findings ( ... The finding of occult invasive and intraepithelial fallopian tube carcinomas in prophylactically removed specimens from ... The lack of proven screening tools for early detection and the high mortality of ovarian serous carcinoma (OSC), particularly ... These multiple foci are thought to represent monoclonal disease, unlike endometrioid carcinomas, which have been shown to have ...
  • The diagnosis of endometrioid adenocarcinoma can also be made if there is extensive papillary pattern or infiltrative glands with desmoplastic response . (webpathology.com)
  • This is an open label Phase 1b/2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or in combination with ultralow dose gemcitabine in participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSignature® test status. (uclahealth.org)
  • Pernick N. Endometrioid adenocarcinoma. (pathologyoutlines.com)
  • Endometrial cancer is usually endometrioid adenocarcinoma. (msdmanuals.com)
  • Загальні джерела літератури Endometrial cancer is usually endometrioid adenocarcinoma. (msdmanuals.com)
  • Endometrioid adenocarcinoma (grades 1 and 2) is the most common histology. (msdmanuals.com)
  • Uterine cancers were classified by histologic type (endometrioid carcinoma, other carcinoma, carcinosarcoma, and sarcoma). (cdc.gov)
  • Other histologic subtypes include adenosquamous, clear cell, and papillary serous carcinomas. (medscape.com)
  • Endometrioid tumors are a class of tumor characterized by a resemblance to endometrium/ endometrial carcinoma, and over a third of cases have focal squamous differentiation. (wikipedia.org)
  • Endometrioid carcinoma can also arise in the endometrium. (wikipedia.org)
  • Relative incidences of endometrial carcinomas by histopathology, being endometrioid in a majority of cases Light microscopy shows tubular glands, resembling endometrium. (wikipedia.org)
  • Endometrial carcinoma usually appears as thickening of the endometrium though may appear as a polypoid mass. (radiopaedia.org)
  • Carcinoma of the endometrium is uncommon in women younger than 40 years of age. (slideserve.com)
  • Approximately 95% of these malignancies are carcinomas of the endometrium . (medscape.com)
  • Tumors located in central portions of the prostate are, in our opinion, morphologic variants of usual prostatic carcinomas, and apparently arise in prostatic ducts. (nih.gov)
  • However, as explained below, recent morphologic findings and molecular analyses have demonstrated that each morphologic subtype of ovarian carcinoma might be derived from a Müllerian-type epithelium. (biomedcentral.com)
  • Epithelial carcinoma makes up 85% to 90% of ovarian/fallopian tube cancers. (cancer.net)
  • 10 ] Further, among carriers of deleterious mutations in BRCA1 or BRCA2, increasing evidence suggests that many tumors previously classified as ovarian high-grade serous carcinoma may develop from malignant cells arising in the tubal epithelium (serous tubal intraepithelial carcinoma [STIC]), although these tumors continue to be referred to as ovarian cancers in most writings. (uofmhealth.org)
  • Based on the model of development of serous tubal intraepithelial carcinomas, there are several theories or pathways by which serous cancers metastasize. (ascopost.com)
  • Epithelial ovarian carcinomas (EOC's) account for 85 to 90 percent of all cancers of the ovaries. (news-medical.net)
  • We report herein the newly described molecular abnormalities in epithelial ovarian cancers (carcinomas). (biomedcentral.com)
  • Endometrioid adenocarcinomas account for about 75 to 80% of endometrial cancers. (msdmanuals.com)
  • L'objectif de cette étude était de déterminer la fréquence des cancers gynécologiques en pratique oncologique à Lomé et d'en étudier les aspects épidémiologiques et histo-cliniques. (bvsalud.org)
  • Il s'agitd'une étude rétrospective et descriptive portant sur tous les cancers gynécologiques reçus en oncologie entre le 1erJanvier 2016 et le 31 Décembre 2021. (bvsalud.org)
  • ces cancers ont ete diagnostiques au stade avance d'ou les difficultes dans leur prise en charge chirurgicale. (bvsalud.org)
  • En consequence notre objectif a ete d'etudier la place et les caracteres de la chirurgie dans la prise en charge de ces cancers. (bvsalud.org)
  • [ 1 ] Most endometrial cancers are of endometrioid type and are associated with exposure to unopposed estrogen . (medscape.com)
  • Results: The preoperative biopsies were all typical ovarian serous or endometrioid adenocarcinomas. (bmj.com)
  • Approximately eighty percent of endometrial carcinomas are endometrioid adenocarcinomas. (medscape.com)
  • Type II tumors are usually high-grade and include grade 3 endometrioid carcinomas and tumors with nonendometrioid histology (eg, serous, clear cell, mixed cell, undifferentiated, carcinosarcoma). (msdmanuals.com)
  • Patients with endometrioid cancer and grade 1 or 2 histology localized to the uterus may undergo hysterectomy only and require no extensive dissection of lymph nodes. (medscape.com)
  • Participant must have histologically documented, platinum resistant, advanced (metastatic and/or unresectable) high-grade serous/endometrioid ovarian, primary peritoneal, or fallopian tube cancer. (uclahealth.org)
  • Because of their common features, high-grade serous ovarian, fallopian tube, and peritoneal carcinomas are considered one clinical entity and referred to as a single entity (epithelial ovarian carcinoma or high-grade serous ovarian cancer). (ascopost.com)
  • 176 patients diagnosed with epithelial ovarian carcinoma after staging laparotomy between January 2002 and May 2010 were evaluated retrospectively. (hindawi.com)
  • Type II tumors include high-grade serous carcinoma, malignant mixed mesodermal tumors, and undifferentiated carcinomas. (hindawi.com)
  • subsequently, this group of tumors of the ovary were classified in 1973 by the World Health Organization as "low malignant potential ovarian tumor" [ 2 ] and, finally, in 2003 WHO separates them from carcinomas and call them borderline tumors. (intechopen.com)
  • Reported rates of mucinous carcinoma diagnoses have declined dramatically, but expert pathology reviews suggest that this reflects increased recognition of metastases from occult gastrointestinal primary tumors to the ovary, rather than a true decline in rates of ovarian primary tumors. (uofmhealth.org)
  • Carcinoma of the ovary is most common in women over age 60. (news-medical.net)
  • Without immunohistological analysis, it is difficult to distinguish this HCC variant from clear cell carcinoma or metastases of renal cell carcinoma. (karger.com)
  • The intraepithelial carcinomas have been referred to as serous intraepithelial carcinomas (STICs) but our own findings (unpublished data) and recent reports have drawn attention to a spectrum of changes that fall short of STICs that we have designated serous tubal intraepithelial lesions (STILs). (hindawi.com)
  • Early investigators reported on serous tubal intraepithelial carcinomas, which developed in the distal fallopian tubes. (ascopost.com)
  • Findings revealed that 59% to 71% were associated with serous tubal intraepithelial carcinomas after careful inspection of the fallopian tubes. (ascopost.com)
  • They are part of the surface epithelial tumor group of ovarian neoplasms (10-20% of which are the endometrioid type). (wikipedia.org)
  • A stepwise model of progression from cystadenomas to low-grade carcinomas has been proposed for these neoplasms. (hindawi.com)
  • Fifty carcinomas that were partially to completely papillary in nature were examined. (nih.gov)
  • We conclude that a distinction between endometrioid carcinomas and tumors of prostatic ducts does not seem justified and that papillary prostatic carcinomas should be treated like common prostatic cancer. (nih.gov)
  • Unlike the invasive carcinomas, borderline ovarian tumors are characterized by cytoplasmic and nuclear atypia, (element of differential diagnosis with benign tumors), absence of stromal invasion, (element of differential diagnosis with malignant tumors), unusual degree of proliferation of the epithelial cells with cellular stratification including remarkable architectural atypia and the formation of papillary protuberances. (intechopen.com)
  • however, in developing countries, it is much less common than carcinoma of the cervix. (medscape.com)
  • Nonmelanotic skin cancer or carcinoma-in-situ of the cervix, or prostate or localized endometrioid endometrial cancer. (mayo.edu)
  • Carcinoma of cervix is classified as per the WHO classification into primary tumors which are predominantly epithelial tumors, mesenchymal tumors and tumor like lesions, mixed epithelial stromal tumors, melanocytic, germ cell, and lymphoid tumors. (cytojournal.com)
  • Carcinoma cervix is not the only cancer caused by HPV. (cytojournal.com)
  • The category of ovarian borderline tumor or tumor of low-malignant potential, which historically had been considered in the context of ovarian cancer, is now generally considered a nonmalignant entity, although it has a postulated relationship with the development of some histological subtypes of low-grade ovarian carcinomas. (uofmhealth.org)
  • However, the vast majority of malignant ovarian tumors (80%-85%) are classified as epithelial tumors (carcinomas). (biomedcentral.com)
  • In a second pathway, the serous tubal intraepithelial carcinoma metastasizes directly into the peritoneal cavity, seeding it and resulting in early dissemination of metastases. (ascopost.com)
  • Lymphovascular space invasion as a predictive factor for lymph node metastases and survival in endometrioid endometrial cancer - a Swedish Gynecologic Cancer Group (SweGCG) study. (cancercentrum.se)
  • Both clear cell ovarian carcinomas (CCC) and ovarian endometrioid carcinomas (EC) may arise from endometriosis and frequently harbor mutations in the ARID1A tumor suppressor gene. (biomedcentral.com)
  • It is hypothesized that high-grade serous carcinomas among individuals who are not carriers of mutations in BRCA1 or BRCA2 may also develop in the fallopian tube, but few STICs have been identified among these women in the absence of concurrent high-stage disease. (uofmhealth.org)
  • Spatial expression of the FGFR2b splice isoform and its prognosticsignificance in endometrioid endometrial carcinoma (2022) Asmerom T Sengal, Deborah Smith, Cameron E Snell, Samuel Leung, Aline Talhouk, Elizabeth D Williams, Jessica N McAlpine and Pamela M Pollock. (edu.au)
  • 2022): Spatial expression of the FGFR2b splice isoform and its prognostic significance in endometrioid endometrial carcinoma. (edu.au)
  • The first (Type I) pathway leads to borderline tumors, which can develop into low-grade serous, mucinous, endometrioid, and clear cell carcinomas. (hindawi.com)
  • The lack of proven screening tools for early detection and the high mortality of ovarian serous carcinoma (OSC), particularly high grade, have focused attention on identifying putative precursor lesions with distinct morphological and molecular characteristics. (hindawi.com)
  • Risk Stratification of Stage I Grade 3 Endometrioid Endometrial Carcinoma in the Era of Molecular Classification. (bvsalud.org)
  • The role of adjuvant therapy in stage I grade 3 endometrioid endometrial carcinoma ( EEC ) is debatable. (bvsalud.org)
  • Objectives To assess the effects on relative survival of established and new prognostic factors in stage I-III grade 1-3 endometrioid endometrial carcinoma and in the subgroup of stage I grade 1-2. (bmj.com)
  • Methods This was a population-based, retrospective study including all women (n=1113) in the western Swedish healthcare region diagnosed with International Federation of Gynecology and Obstetrics (FIGO) stage I-III grade 1-3 endometrioid endometrial carcinoma in 2006-2011. (bmj.com)
  • Conclusion We can conclude that S-phase fraction, DNA ploidy, and p53 overexpression did not improve identification of high-risk patients by stage, grade, and age in stage I-III endometrioid endometrial carcinoma. (bmj.com)
  • It is estimated that 60% of sporadic ovarian carcinomas and the majority of those diagnosed in BRCA1 mutation carriers are of the high-grade serous type [ 4 , 5 ]. (hindawi.com)
  • Ovarian carcinomas consist of several histopathological types, with high-grade serous being both the most common and most lethal. (uofmhealth.org)
  • Further, data suggest that the distinction of high-grade serous carcinomas from other histological types of high-grade carcinomas, particularly endometrioid carcinomas, is not reliable. (uofmhealth.org)
  • The discovery of a serous tubal intraepithelial carcinoma imposes a later risk of high-grade serous cancer. (ascopost.com)
  • This small percentage includes patients with stage IA or IB (grade 1) serous, mucinous, endometrioid, and Brenner tumors. (medscape.com)
  • However, it is not known whether the precursor cells from the serous tubal intraepithelial carcinoma implant on the peritoneal surface or float freely in the peritoneal fluid prior to undergoing a pivotal genomic change, resulting in tumor development. (ascopost.com)
  • Serous carcinomas are thought to be derived from the fallopian tubes through foci of endosalpingiosis, which are inclusion cysts from the tubal epithelium at the ovarian and peritoneal surface. (biomedcentral.com)
  • Ovarian carcinomas are characterized by a Müllerian morphology although the ovaries do not originate from the Müllerian ducts. (biomedcentral.com)
  • Staging of endometrial carcinoma is based on the FIGO staging system, which is a surgical and pathological staging following total abdominal hysterectomy , salpingo-oophorectomy, lymphadenectomy, and peritoneal washings. (radiopaedia.org)
  • Aims: Traditionally, advanced stage ovarian carcinoma is treated by debulking surgery followed by chemotherapy. (bmj.com)
  • This study aims to describe the morphological features found in ovarian carcinoma after chemotherapy because these have not been detailed previously. (bmj.com)
  • Methods: Histological sections were examined from 18 cases of ovarian carcinoma that had been treated by preoperative chemotherapy. (bmj.com)
  • Histologically, most of them are serous or mucinous, but endometrioid, clear cell, Brenner (transitional cell) or mixed histotypes can be also seen. (intechopen.com)
  • OBJECTIVES: I. Evaluate the efficacy of paclitaxel and carboplatin with amifostine on progression free survival and overall survival in patients with metastatic or recurrent epithelial endometrial carcinoma not amenable to surgery or radiotherapy. (knowcancer.com)
  • Primary treatment and relative survival by stage and age in vulvar squamous cell carcinoma: A population-based SweGCG study. (cancercentrum.se)
  • The association of endometriosis with ovarian cancer is stronger for nonserous subtypes, especially clear cell carcinoma and endometrioid subtypes. (uofmhealth.org)
  • There is an association with endometriosis and concurrent primary endometrial carcinoma (endometrial cancer). (wikipedia.org)
  • We sought to define the agreement between Post Operative Radiation Therapy in Endometrial Carcinoma 1 (PORTEC-1) high-intermediate risk (HIR) and Gynecologic Oncology Group (GOG)-99 HIR criteria, assess their concordance with The Cancer Genome Atlas molecular subtypes, and evaluate oncologic outcomes in this population . (bvsalud.org)
  • Type II (20%) arises in the setting of endometrial atrophy, in females between 65 to 75 years old, and endometrial intraepithelial carcinoma. (radiopaedia.org)
  • Immunohistochemical analysis of paraffin-embedded human squamous cell lung carcinoma using Btk (D3H5) Rabbit mAb performed on the Leica ® Bond â„¢ Rx. (cellsignal.com)